USRE42376E1 - Substituted 3-cyanoquinolines - Google Patents
Substituted 3-cyanoquinolines Download PDFInfo
- Publication number
- USRE42376E1 USRE42376E1 US12/785,269 US78526910A USRE42376E US RE42376 E1 USRE42376 E1 US RE42376E1 US 78526910 A US78526910 A US 78526910A US RE42376 E USRE42376 E US RE42376E
- Authority
- US
- United States
- Prior art keywords
- carbon atoms
- methoxy
- pharmaceutically acceptable
- acceptable salt
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active, expires
Links
- 0 [1*]C1=C2C(CCC)=C(C#N)C=NC2=C([4*])C(C)=C1C Chemical compound [1*]C1=C2C(CCC)=C(C#N)C=NC2=C([4*])C(C)=C1C 0.000 description 107
- NQRYJNQNLNOLGT-UHFFFAOYSA-N C1CCNCC1 Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 5
- UBZJXAQDXUGXIZ-UHFFFAOYSA-N C1=CC=C2N=CC=CC2=C1.C1=CC=C2N=CN=CC2=C1 Chemical compound C1=CC=C2N=CC=CC2=C1.C1=CC=C2N=CN=CC2=C1 UBZJXAQDXUGXIZ-UHFFFAOYSA-N 0.000 description 1
- BCLSJHWBDUYDTR-UHFFFAOYSA-N CCCNCCO Chemical compound CCCNCCO BCLSJHWBDUYDTR-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
Definitions
- This invention relates to certain substituted 3-cyano quinoline compounds as well as the pharmaceutically acceptable salts thereof.
- the compounds of the present invention inhibit the action of certain growth factor receptor protein tyrosine kinases (PTK) and other protein kinases thereby inhibiting the abnormal growth of certain cell types.
- the compounds of this invention are therefore useful for the treatment of certain diseases that are the result of deregulation of these PTKs.
- the compounds of this invention are anti-cancer agents and are useful for the treatment of cancer in mammals.
- the compounds of this invention are useful for the treatment of polycystic kidney disease in mammals.
- This invention also relates to the manufacture of said 3-cyano quinolines, their use for the treatment of cancer and polycystic kidney disease, and the pharmaceutical preparations containing them.
- Protein tyrosine kinases are a class of enzymes that catalyze the transfer of a phosphate group from ATP to a tyrosine residue located on a protein substrate. Protein tyrosine kinases clearly play a role in normal cell growth. Many of the growth factor receptor proteins function as tyrosine kinases and it is by this process that they effect signaling. The interaction of growth factors with these receptors is a necessary event in normal regulation of cell growth. However, under certain conditions, as a result of either mutation or overexpression, these receptors can become deregulated; the result of which is uncontrolled cell proliferation which can lead to tumor growth and ultimately to the disease known as cancer [Wilks A. F., Adv.
- EGF-R kinase epidermal growth factor receptor kinase
- erbB-2 the product produced by the erbB-2 (also referred to as the neu or HER2) oncogene.
- an inhibitor of this event a protein tyrosine kinase inhibitor
- a protein tyrosine kinase inhibitor will have therapeutic value for the treatment of cancer and other diseases characterized by uncontrolled or abnormal cell growth.
- overexpression of the receptor kinase product of the erbB-2 oncogene has been associated with human breast and ovarian cancers [Slamon, D. J., et. al., Science, 244, 707 (1989) and Science, 235, 1146 (1987)].
- Deregulation of EGF-R kinase has been associated with epidermoid tumors [Reiss, M., et.
- the compounds of this invention inhibit the kinase activity of EGF-R and are therefore useful for treating certain disease states, such as cancer, that result, at least in part, from deregulation of this receptor.
- the compounds of this invention are also useful for the treatment and prevention of certain pre-cancerous conditions, such as the growth of colon polyps, that result, at least in part, from deregulation of this receptor.
- the mitogen-activated protein kinase (MAPK) pathway is a major pathway in the cellular signal transduction cascade from growth factors to the cell nucleus.
- the pathway involves kinases at two levels: MAP kinase kinases (MAPKK), and their substrates MAP kinases (MAPK).
- MAPKK MAP kinase kinases
- MAPK MAP kinases
- the compounds of this invention can inhibit the action of two of these kinases: MEK, a MAP kinase kinase, and its substrate ERK, a MAP kinase.
- MEK is activated by phosphorylation on two serine residues by upstream kinases such as members of the raf family. When activated, MEK catalyzes phosphorylation on a threonine and a tyrosine residue of ERK. The activated ERK then phosphorylates and activates transcription factors in the nucleus, such as fos and jun, or other cellular targets with PXT/SP sequences. ERK, a p42 MAPK is found to be essential for cell proliferation and differentiation. Over-expression and/or over-activation of Mek or ERK has been found to be associated with various human cancers (For example, Vimala S. Sivaraman, Hsien-yu Wang, Gerard J.
- the compounds of this invention can inhibit the coupled action of MEK and ERK, they are useful for the treatment of diseases such as cancer which are characterized by uncontrolled cell proliferation and which, at least in part, depend on the MAPK pathway.
- ECK Epithelial Cell Kinase
- RPTK receptor protein tyrosine kinase
- EPH Epithelial Cell Kinase
- ECK has subsequently been shown to be expressed on vascular endothelial cells, smooth muscle cells, and fibroblasts.
- ECK is a type I transmembrane glycoprotein with the extracellular ligand-binding domain consisting of a cysteine-rich region followed by three fibronectin type III repeats.
- ECK The intracellular domain of ECK possesses a tyrosine kinase catalytic domain that initiates a signal transduction cascade reflecting the ECK function.
- ECK binds and is subsequently activated by its counter-receptor, Ligand for Eph-Related Kinase (LERK)-1, which is an immediate early response gene product readily inducible in a lineage-unrestricted manner with proinflammatory cytokines such as IL-1 or TNF.
- Soluble LERK-1 has been shown to stimulate angiogenesis in part by stimulating ECK in a murine model of corneal angiogenesis.
- tumor cells of various lineages constitutively express LERK-1 and this expression can further be upregulated by hypoxia and proinflammatory cytokines. Many of these tumor cells also express ECK at higher levels than their normal counterparts, thereby creating an opportunity for autocrine stimulation via ECK: LERK-1 interaction.
- ECK LERK-1 interaction
- the increased expression of both ECK and LERK-1 has been correlated with the transformation of melanomas from the noninvasive horizontal phase of growth into very invasive vertically growing metastatic melanomas. Together, the ECK: LERK-1 interaction is believed to promote tumor growth via its tumor growth promoting and angiogenic effects.
- the inhibition of the ECK tyrosine kinase activity mediating signaling cascade induced by its binding and cross-linking to LERK-1 may be therapeutically beneficial in cancer, inflammatory diseases, and hyperproliferative disorders.
- the compounds of this invention inhibit the tyrosine kinase activity of ECK and are therefore useful for the treatment of the aforementioned disorders.
- vascular endothelial growth Factor is one such angiogenic factor.
- VEGF vascular endothelial permeability in the affected tissues.
- VEGF is also a senescence-preventing survival factor for endothelial cells. Almost all nucleated tissues in the body possess the capability to express VEGF in response to various stimuli including hypoxia, glucose deprivation, advanced glycation products, inflammatory cytokines, etc. Growth-promoting angiogenic effects of VEGF are mediated predominantly via its signaling receptor Kinase insert Domain containing Receptor (KDR).
- KDR signaling receptor Kinase insert Domain containing Receptor
- KDR is a receptor protein tyrosine kinase with an extracellular VEGF-binding domain consisting of 7 immunoglobulin-like domains and a cytoplasmic domain containing the catalytic tyrosine kinase domain split by a kinase-insert region. Binding to VEGF causes dimerization of KDR resulting in its autophosphorylation and initiation of signaling cascade.
- Tyrosine kinase activity of KDR is essential for mediation of its functional effects as a receptor for VEGF. Inhibition of KDR-mediated functional effects by inhibiting KDR's catalytic activity is considered to be an important therapeutic strategy in the treatment of angiogenized disease states including cancer. As is shown below, the compounds of this invention inhibit the tyrosine kinase activity of KDR and are therefore useful for the treatment of the aforementioned disease states.
- the compounds of this invention are certain substituted 3-cyano quinolines.
- the quinoline ring system will be numbered as indicated in the formula below; the numbering for the quinazoline ring system is also shown:
- the patent applications WO 96/09294 and WO-9813350 describe inhibitors of protein tyrosine kinases that include 4-anilino quinolines with a large variety of substituents on positions 5-8 but which must also have a hydrogen or fluorine atom at position 3.
- the U.S. Pat. No. 5,480,883 describes quinoline derivatives that are inhibitors of protein tyrosine kinases but these derivatives do not have the unique combination of substituents, including the 3-cyano group, contained in the compounds of the present invention.
- the applications WO-9802434 and WO-9802438 describe quinoline derivatives that are tyrosine kinase inhibitors but these quinolines do not have the important 3-cyano substituent.
- quinazoline derivatives that are similar, in some respects, to the compounds of this invention are known to be inhibitors of protein tyrosine kinases.
- the application EP-520722 describes 4-anilinoquinazolines that contain simple substituents such as chloro, trifluoromethyl, or nitro groups at positions 5 to 8.
- the application EP-566226 is similar but with a much larger variety of substituents now allowed at positions 5 to 8.
- the application WO-9609294 describes compounds with similar substituents at positions 5 to 8 and with the substituent at to 4-position consisting of some polycyclic ring systems.
- Some simple substituted quinazolines are also described in the applications WO-9524190, WO-9521613, and WO-9515758.
- the applications EP-602851 and WO-9523141 cover similar quinazoline derivatives where the aryl group attached at position 4 can be a variety of heterocyclic ring structures.
- the application EP-635498 describes certain quinazoline derivatives that have alkenoylamino and alkynoylamino groups among the substituents at position 6 and a halogen atom at position 7.
- the application WO-9519774 describes compounds where one or more of the carbon atoms at positions 5-8 can be replaced with heteroatoms resulting in a large variety of bicyclic systems where the left-hand ring is a 5 and 6-membered heterocyclic ring; in addition, a variety of substituents are allowed on the left-hand ring.
- the application EP-682027-A1 describes certain pyrrolopyrimidine inhibitors of PTKs.
- the application WO-9519970 describes compounds in which the left-hand aromatic ring of the basic quinazoline structure has been replaced with a wide variety of different heterocyclic rings so that the resulting inhibitors are tricyclic.
- the application EP-635507 describes quinazolines where an additional 5 or 6-membered heterocyclic ring with optional substitution is fused at positions 5 and 6.
- This invention provides a compound of formula 1:
- the pharmaceutically acceptable salts are those derived from such organic and inorganic acids as: acetic, lactic, citric, tartaric, succinic, maleic, malonic, gluconic, hydrochloric, hydrobromic, phosphoric, nitric, sulfuric, methanesulfonic, and similarly known acceptable acids.
- alkyl portion of the alkyl, alkoxy, alkanoyloxy, alkoxymethyl, alkanoyloxymethyl, alkylsulphinyl, alkylsulphonyl, aminoalkyl, N-alkylaminoalkyl, N,N-dialkylaminoalkyl, N-alkylaminoalkoxy, N,N-dialkylaminoalkoxy, alkylsulfonamido, carboalkoxy, carboalkyl, carboxyalkyl, carboalkoxyalkyl, alkanoylamino, N-alkylcarbamoyl, and N,N-dialkylcarbamoyl substituents include both straight chain as well as branched carbon chains.
- the alkenyl portion of the alkenyl, alkenoyloxymethyl, alkenyloxy, alkenylsulfonamido, substituents include both straight chain as well as branched carbon chains and one or more sites of unsaturation and all possible configurational isomers.
- the alkynyl portion of the alkynyl, alkynoyloxymethyl, alkynylsulfonamido, alkynyloxy, substituents include both straight chain as well as branched carbon chains and one or more sites of unsaturation.
- Carboxy is defined as a —CO 2 H radical.
- Carboalkoxy of 2-7 carbon atoms is defined as a —CO 2 R′′ radical, where R′′ is an alkyl radical of 1-6 carbon atoms.
- Carboxyalkyl is defined as a HO 2 C—R′′′ radical where R′′′ is a divalent alkyl radical of 1-6 carbon atoms.
- Carboalkoxyalkyl is defined as a R′′O 2 C—R′′′— radical where R′′′ is a divalent akyl radical and where R′′ and R′′′ together have 2-7 carbon atoms.
- Carboalkyl is defined as a —COR′′ radical, where R′′ is an alkyl radical of 1-6 carbon atoms.
- Alkanoyloxy is defined as a —OCOR′′ radical, where R′′ is an alkyl radical of 1-6 carbon atoms.
- Alkanoyloxymethyl is defined as R′′CO 2 CH 2 — radical, where R′′ is an alkyl radical of 1-6 carbon atoms.
- Alkoxymethyl is defined as R′′OCH 2 — radical, where R′′ is an alkyl radical of 1-6 carbon atoms.
- Alkylsulphinyl is defined as R′′SO— radical, where R′′ is an alkyl radical of 1-6 carbon atoms.
- Alkylsulphonyl is defined as R′′SO 2 — radical, where R′′ is an alkyl radical of 1-6 carbon atoms.
- Alkylsulfonamido, alkenylsulfonamido, alkynylsulfonamido are defined as R′′SO 2 NH— radical, where R′′ is an alkyl radical of 1-6 carbon atoms, an alkenyl radical of 2-6 carbon atoms, or an alkynyl radical of 2-6 carbon atoms, respectively.
- N-alkylcarbamoyl is defined as R′′NHCO— radical, where R′′ is an alkyl radical of 1-6 carbon atoms.
- N,N-dialkylcarbamoyl is defined as R′′ R′NCO— radical, where R′′ is an alkyl radical of 1-6 carbon atoms, R′ is an alkyl radical of 1-6 carbon atoms and R′, and R′′ may be the same or different.
- R′′ is an alkyl radical of 1-6 carbon atoms
- R′ is an alkyl radical of 1-6 carbon atoms and R′
- R′′ may be the same or different.
- Het is a heterocycle, as defined above which may be optionally mono- or di-substituted with R 6 on carbon or nitrogen, optionally mono- or di-substituted on carbon with hydroxy, —N(R 6 ) 2 , or —OR 6 , optionally mono or di-substituted on carbon with with —(C(R 6 ) 2 ) s OR 6 or —(C (R 6 ) 2 ) s N(R 6 ) 2 , and optionally mono or di-substituted on a saturated carbon with divalent radicals —O— or —O(C(R 6 ) 2 ) s O— (carbonyl and ketal groups, respectively); in some cases when Het is substituted with —O— (carbonyl), the carbonyl group can be hydrated.
- Het is a nitrogen containing heterocycle which also contains an unsaturated carbon-nitrogen bond
- that nitrogen atom of the heterocycle may be bonded to carbon when W is a bond and the resulting heterocycle will bear a positive charge.
- substitution may be on a ring carbon, or in the case of a nitrogen containing heterocycle, which also contains a saturated carbon-nitrogen, such nitrogen may be substituted with R 6 or in the case of a nitrogen containing heterocycle, which also contains an unsaturated carbon-nitrogen, such nitrogen may be substituted with R 6 in with case the heterocycle will bear a positive charge.
- Preferred heterocycles include pyridine, 2,6-disubstituted morpholine, 2,5-disubsti tuted thiomorpholine, 2-substituted imidazole, substituted thiazole, thiazolidine, N-substituted imidazole, N-substituted 1,4-piperazine, N-subsitituted piperadine, dioxane, 1,3-dioxolane, and N-substituted pyrrolidine.
- the compounds of this invention may contain one or more asymmetric carbons atoms; in such cases, the compounds of this invention include the individual diasteromers, the racemates, and the individual R and S entantiomers thereof. Some of the compound of this invention may contain one or more double bonds; in such cases, the compounds of this invention include each of the possible configurational isomers as well as mixtures of these isomers.
- X′ is cycloalkyl of 3 to 7 carbon atoms, which may be optionally substituted with one or more alkyl of 1 to 6 carbon atom groups; or is a pyridinyl, pyrimidinyl, or phenyl ring wherein the pyridinyl, pyrimidinyl, or phenyl ring may be optionally mono- di-, or tri-substituted with a substituent selected from the group consisting of halogen, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, azido, hydroxyalkyl of 1-6 carbon atoms, halomethyl, alkoxymethyl of 2-7 carbon atoms, alkoxy of 1-6 carbon atoms, alkylthio of 1-6 carbon atoms, hydroxy
- R 1 ′, R 2 ′, R 3 ′, and R′ 4 are each, independently, hydrogen, halogeno, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, alkenyloxy of 2-6 carbon atoms, alkynyloxy of 2-6 carbon atoms, halomethyl, alkoxymethyl of 2-7 carbon atoms, alkoxy of 1-6 carbon atoms, alkylthio of 1-6 carbon atoms, alkylsulphinyl of 1-6 carbon atoms, alkylsulphonyl of 1-6 carbon atoms, alkylsulfonamido of 1-6 carbon atoms, trifluoromethyl, cyano, nitro, carboxy, carboalkyl of 2-7 carbon atoms, phenoxy, phenyl, thiophenoxy, benzyl, alkoxyamino of 1-4 carbon atoms, dialkylamino of
- a quinoline-3-carboxylic acid ester of Formula 2 is hydrolyzed with base to furnish a carboxylic acid of Formula 3.
- the carboxylic acid group of 3 is converted to an acyl imidazole by heating it with carbonyldiimidazole in an inert solvent such as dimethylformamide (DMF) followed by the addition of ammonia to give the amide 4.
- a dehydrating agent such as trifluoroacetic anhydride in pyridine, phosphorous pentoxide in an inert solvent, or the like gives the 3-cyano quinolines, 5, of this invention.
- any of the intermediates have an asymmetric carbon atom, they can be used as the racemate or as the individual R or S entantiomers in which case the compounds of this invention will be in the racemic or R and S optically active forms, respectively.
- the quinoline-3-carboxylic acid esters of Formula 2, the quinoline-3-carboxylic acids of Formula 3, and the quinoline-3-carboxylic amides of Formula 4 needed to prepare the compounds of this invention are either already known to the art or can be prepared by procedures known in the art as detailed in the following references: Sarges, Reinhard; Gallagher, Andrea; Chambers, Timothy J.; Yeh, Li An, J. Med.
- isomers can be separated by methods well known in the art including, but not limited to, fractional crystallization and chromatographic methods. The separated isomers can then be converted separately to the compounds of the invention. Alternatively, the isomers can be separated at a later stage of the synthesis. Heating compounds 9 with or without solvent with a chlorinating agent such as phosphorous oxychloride or phosphorous pentachloride gives the 4-chloro-3-cyano quinolines of Formula 10.
- diasteriomers may be present; these can be separated by methods well known in the art including, but not limited to, fractional crystallization and chromatographic methods.
- R 1 , G 2, G 1 , and R 4 moieties may first have to be used in protected form prior to reaction with reagent 7.
- Suitable protecting groups include, but are not limited to, tert-butoxycarbonyl (BOC) and benzyloxycarbonyl (CBZ) protecting groups.
- BOC tert-butoxycarbonyl
- CBZ benzyloxycarbonyl
- the hydroxyl groups may first have to be used in protected form prior to reaction with reagent 7.
- Suitable protecting groups include, but are not limited to, t-butyldimethylsilyl, tetrahydropyranyl, or benzyl protecting groups.
- the first two protecting groups can be removed from the final products of formula 12 by treatment with an acid such as acetic acid or hydrochloric acid while the latter protecting group can be removed by catalytic hydrogenation.
- intermediate 15 (identical to intermediate 9 of Flowsheet 2) can also be prepared as describe below in Flowsheet 3. Heating the substituted aniline of Formula 13 with dimethylformamide dimethyl acetal with or without a solvent gives intermediates for Formula 14.
- the reaction of 14 with the lithium anion of acetonitrile prepared using a base such as n-butyl lithium or the like in an inert solvent gives the 3-cyano quinolones, 15, or the 3-cyano-4-hydroxy quinoline tautomers thereof which can be converted to the compounds of this invention.
- R 1 , G 2 , G 1 , and R 4 moieties may first have to be used in protected form.
- Suitable protecting groups include, but are not limited to, tert-butoxycarbonyl (BOC) and benzyloxycarbonyl (CBZ) protecting groups.
- the former protecting group can be removed from the final products of Formula 15 by treatment with an acid such as trifluoroactic acid while the latter protecting group can be removed by catalytic hydrogenation.
- the hydroxyl groups may first have to be used in protected form.
- Suitable protecting groups include, but are not limited to, t-butyldimethylsilyl, tetrahydropyranyl, or benzyl protecting groups.
- the first two protecting groups can be removed from the final products of formula 15 by treatment with an acid such as acetic acid or hydrochloric acid while the latter protecting group can be removed by catalytic hydrogenation.
- R 10 is alkyl of 1-6 carbon atoms (preferably isobutyl).
- R 2 ′ is a radical selected from the group consisting of:
- R 6 , R 3 , R 5 , J, s, r, u, and v are defined.
- a 4-chloro-3-cyano-6-nitroquinoline, 16 can be reacted with an amine or aniline 17 by heating in an inert solvent such as tetrahydrofuran, butanol, or methoxyethanol to give compounds of Formula 20 where Z is —NH—.
- the reaction of 16 with a mercaptan or thiophenol 18 in an inert solvent can be accomplished using a base such as sodium hydride to give compounds of Formula 20 where Z is —S—.
- the reaction of 16 with a alcohol or phenol 19 in an inert solvent can be accomplished using a base such as sodium hydride to give compounds of Formula 20 where Z is —O—.
- Compounds of Formula 20 can be reduced to a 6-amino-3-cyano-quinoline, 21, using a reducing agent such as sodium hydrosulfite in a two phase system consisting of tetrahydrofuran and water in the presence of a small amount of phase transfer catalyst or by using iron in refluxing protic solvents containing acetic acid or ammonium chloride.
- Suitable protecting groups include, but are not limited to, tert-butoxycarbonyl (BOC) and benzyloxycarbonyl (CBZ) protecting groups.
- BOC tert-butoxycarbonyl
- CBZ benzyloxycarbonyl
- the former protecting group can be removed from the final products of Formula 24 by treatment with an acid such as trifluoroactic acid while the latter protecting group can be removed by catalytic hydrogenation.
- the hydroxyl groups may first have to be protected prior to anhydride or acid chloride formation.
- Suitable protecting groups include, but are not limited to, t-butyldimethylsilyl, tetrahydropyranyl, or benzyl protecting groups.
- the first two protecting groups can be removed from the final products of Formula 24 by treatment with an acid such as acetic acid or hydrochloric acid while the latter protecting group can be removed by catalytic hydrogenation.
- an acid such as acetic acid or hydrochloric acid
- X contains primary or secondary amino groups or hydroxyl groups
- the same amine or alcohol protecting groups describe above can be used and they can be removed from the products 24 as previously described.
- the intermediates 25 can be converted to the compounds of this invention, 26.
- the temperature and duration of the heating will depend on the reactivity of 27; longer reaction times and higher temperatures may be required when s is greater than 1.
- Treatment of 28 with an alkyl lithium reagent followed by quenching with an atmosphere of dry carbon dioxide furnishes the carboxylic acids of Formula 29.
- These can be converted to mixed anhydrides of Formula 31 using a reagent such as isobutylchloroformate in an inert solvent such as tetrahydrofuran in the presence of a base such as N-methylmorpholine.
- a base such as N-methylmorpholine.
- the reaction of 27 with an alcohol of List B is accomplished using sodium hydride or other non-nucleophic base such as potassium or cesium carbonate in an inert solvent such as tetrahydrofuran, acetone, or N,N-dimethylformamide.
- the alcohol of List B can also be the solvent of the reaction.
- Treatment of 32 with an alkyl lithium reagent followed by quenching with an atmosphere of dry carbon dioxide furnishes the carboxylic acids of Formula 33.
- These can be converted to mixed anhydrides Formula 34 using a reagent such as isobutylchloroformate in an inert solvent such as tetrahydrofuran in the presence of a base such as N-methylmorpholine.
- a base such as N-methylmorpholine.
- alcohols 35 can be protected with a t-butyl dimethysilyl protecting group by the reaction with the respective silyl chloride in methylene chloride in the presence of triethylamine and 4-N,N-dimethylamino pyridine (DMAP).
- DMAP 4-N,N-dimethylamino pyridine
- the resulting protected alcohols, 36 are converted to the acetylenic Grignard reagents which, in turn, are maintained under an atmosphere of dry carbon dioxide to give the carboxylic acids 37.
- the reaction of 46 with an amine of List A gives the compounds of this invention represented by 48 is accomplished by heating in an inert solvent such as tetrahydrofuran or N,N-dimethylformamide, or using potassium or cesium carbonate in acetone.
- an inert solvent such as tetrahydrofuran or N,N-dimethylformamide
- potassium or cesium carbonate in acetone. The temperature and duration of the heating will depend on the reactivity of 46; longer reaction times and higher temperatures may be required when s is greater than 1.
- 45b can be converted to 47b or 48b.
- These acid can be converted to the respective carboxylic acid chlorides 51 or 56 by using oxalyl chloride and catalytic N,N-dimethylforrnamide in an inert solvent or respective mixed anhydrides 55 or 59 by using isobutyl chloroformate and an organic base such as N-methylmorpholine.
- the leaving group in compounds represented by Formula 52 can be displaced by the amines of List A or the alcohols of List B by using procedures previously described to give the intermediates 57 and 53, respectively.
- These carboxylic acid chlorides 51 and 56 and these anhydrides 55 and 59 can be used to prepare some of the compounds of this invention by using the methods outlined herein above in the Flowsheets.
- A is the radical: —N(R′) 2 , —OR′, or ⁇ J′ wherein —N(R′) 2 is derived from the amines of List A, —OR′ are derived from the alcohols of List B, and J′ is a leaving group as defined previously.
- the reaction of 62 with an alcohol of List B is accomplished using sodium hydride or other non-nucleophic base such as potassium or cesium carbonate in an inert solvent such as tetrahydrofuran, acetone, or N,N-dimethylformamide to give the compounds of this invention represented by 63.
- the alcohol of List B can also be the solvent of the reaction.
- the reaction of 62 with an amine of List A to give the compounds of this invention represented by 64 is accomplished by heating in an inert solvent such as tetrahydrofuran or N,N-dimethylformamide. The temperature and duration of the heating will depend on the reactivity of 62; longer reaction times and higher temperatures may be required when s is greater than 1.
- the carboxylic acid chlorides and mixed anhydrides listed in List C can be used to prepare the analogous compounds of this invention.
- 61b can be converted to 63b and 64b via the intermediate 62b.
- reaction of 62 or 62b with a nitrogen containing heterocycle HET which also contains an unsaturated carbon-nitrogen bond is accomplished by refluxing in an inert solvent and gives the compounds of this invention 64c and 64d, respectively where the compound bears a positive charge.
- Some of the compounds of this invention can be prepared as outline below in Flowsheet 10 wherein R 1 , G 2 , R 3 , R 4 , R 6 , R 10 , X, Z, J′, n, and r are as defined above.
- the acetylenic alcohols 65 can be coupled to the halides, mesylates, or tosylates 66 using a base such as sodium hydride in an inert solvent such as tetrahydrofuran.
- the resulting acetylene, 67 is then treated with an alkyl lithium reagent at low temperature. Maintaining the reaction under an atmosphere of carbon dioxide then gives the carboxylic acids 68.
- the intermediates 67 can be prepared starting with an alcohol 71 by first treating it with a base such as sodium hydride in an inert solvent such as tetrahydrofuran and then adding an acetylene 72 that has an appropriate leaving group.
- a base such as sodium hydride
- an inert solvent such as tetrahydrofuran
- an acetylene 72 that has an appropriate leaving group.
- the amino alcohols represented by the formula: (R 6 ) 2 N—(C(R 6 ) 2 ) r —OH by reacting with 72, and applying the chemistry of Flowsheet 10 can be converted to the compounds of this invention represented by the formulas:
- 69b can be converted to the compounds of this invention represented by 70b.
- Refluxing 73 and 74 in an a solvent such as ethanol gives the intermediate 75 which can react with an amine in refluxing ethanol to give the compounds of this invention represented by Formula 76.
- Treating 75 with an excess of a sodium alkoxide in an inert solvent or a solvent from which the alkoxide is derived gives the compounds of this invention of Formula 77.
- 74b can be converted to 76b or 77b.
- Compounds of this invention represented by Formula 83 can be prepared as shown in Flowsheet 12 wherein R 1 , G 2 , R 4 , R 6 , R 3 , R 10 , X, Z, n, and r are as defined above.
- the reaction of the mecapto carboxylic acids 78 with the reagents 79 give the compounds represented by Formula 80.
- 80 can be prepared from the mercaptan R 3 SH using the mercapto acid 78, triethylamine and 2,2′-dipyridyl disulfide. Mixed anhydride formation to give 81 followed by condensation with the 6-amino-3-cyanoquinolines 82 give the compounds of this invention.
- Compounds of this invention represented by Formulas 86-88 can be prepared as shown in Flowsheet 13 wherein R 1 , G 2 , R 1 , R 4 , R 5 , J′, X, Z, and n are as defined above.
- Q′ is alkyl of 1-6 hydrogen atoms, alkoxy of 1-6 hydrogen catoms, hydroxy, or hydrogen.
- Akylation of 84 with the 6-amino-3-cyanoquinolines 85 can be accomplished by heating in an inert solvent such as N,N-dimethylformamide using a base such as potassium carbonate to give the compounds of this invention represented by the Formula 86.
- the ester group can be hydrolyzed to an acid using a base such as sodium hydroxide in methanol.
- a base such as sodium hydroxide in methanol.
- 85b can be converted to 86b-88b.
- Compounds of this invention represented by Formula 93 can be prepared as shown in Flowsheet 14 wherein R 1 , G 2 , R 1 , R 4 , R 5 , X, Z, and n are as defined above.
- the reaction of reagent 91 with the 6-amino-3-cyanoquinolines 92 is accomplished using an excess of an organic base such as triethylamine and an inert solvent such as tetrahydrofuran to give compounds of this invention represented by Formula 93.
- Compounds of this invention represented by Formula 96 can be prepared as shown in Flowsheet 15 wherein R 1 , G 1 , R 1 , R 4 , R 5 , R 6 , W, Het, X, Z, k, and n are as defined above by the Mitsunobu reaction of phenol 94 and an alcohol 95 in an inert solvent. Alternatively, the Mitsunobu reaction can be applied to compound 97 to give 98. This compound can be converted to 96 as described above in Flowsheet 4. The heterocycle can be introduced at the 6-position by using the corresponding compounds where G 1 is hydroxy and G 2 is located at the 7-position.
- R 1 , G 1 , G 2 , or R 4 is a nitro group
- it can be converted to the corresponding amino group by reduction using a reducing agent such as iron in acetic acid or by catalytic hydrogenation.
- a reducing agent such as iron in acetic acid or by catalytic hydrogenation.
- R 1 , G 1 , G 2 , or R 4 is an amino group
- it can be converted to the corresponding dialkyamino group of 2 to 12 carbon atoms by alkylation with at least two equivalents of an alkyl halide of 1 to 6 carbon atoms by heating in an inert solvent or by reductive alkylation using an aldehyde of 1 to 6 carbon atoms and a reducing agent such as sodium cyanoborohydride.
- R 1 , G 1 , G 2 , or R 4 is a methoxy group
- it can be converted to the corresponding hydroxy group by reaction with a demethylating agent such as boron tribromide in an inert solvent or by heating with pyridinium chloride with or without solvent.
- R 1 , G 1 , G 2 , or R 4 is an amino group
- it can be converted to the corresponding alkylsulfonamido, alkenylsulfonamido, or alkynylsulfonamido group of 2 to 6 carbon atoms by the reaction with an alkylsulfonyl chloride, alkenylsulfonyl chloride, or alkynylsulfonyl chloride, respectively, in an inert solvent using a basic catalyst such as triethylamine or pyridine.
- a basic catalyst such as triethylamine or pyridine
- R 1 , G 1 , G 2 , or R 4 is an amino group
- it can be converted to the corresponding alkyamino group of 1 to 6 carbon atoms by alkylation with one equivalent of an alkyl halide of 1 to 6 carbon atoms by heating in an inert solvent or by reductive alkylation using an aldehyde of 1 to 6 carbon atoms and a reducing agent such as sodium cyanoborohydride in a protic solvent such as water or alcohol, or mixtures thereof.
- R 1 , G 1 , G 2 , or R 4 is hydroxy, it can be converted to the corresponding alkanoyloxy, group of 1-6 carbon atoms by reaction with an appropriate carboxylic acid chloride, anhydride, or mixed anhydride in a inert solvent using pyridine or a trialkylamine as a catalyst.
- R 1 , G 1 , G 2 , or R 4 is hydroxy, it can be converted to the corresponding alkenoyloxy group of 1-6 carbon atoms by reaction with an appropriate carboxylic acid chloride, anhydride, or mixed anhydride in an inert solvent using pyridine or a trialkylamine as a catalyst.
- R 1 , G 1 , G 2 , or R 4 is hydroxy, it can be converted to the corresponding alkynoyloxy group of 1-6 carbon atoms by reaction with an appropriate carboxylic acid chloride, anhydride, or mixed anhydride in a inert solvent using pyridine or a trialkylamine as a catalyst.
- R 1 , G 1 , G 2 , or R 4 is carboxy or a carboalkoxy group of 2-7 carbon atoms
- it can be converted to the corresponding hydroxymethyl group by reduction with an appropriate reducing agent such as borane, lithium borohydride, or lithium aluminum hydride in a inert solvent
- the hydroxymethyl group in turn, can be converted to the corresponding halomethyl group by reaction in an inert solvent with a halogenating reagent such as phosphorous tribromide to give a bromomethyl group, or phosphorous pentachloride to give a chloromethyl group.
- a halogenating reagent such as phosphorous tribromide to give a bromomethyl group, or phosphorous pentachloride to give a chloromethyl group.
- the hydroxymethyl group can be acylated with an appropriate acid chloride, anhydride, or mixed anhydride in an inert solvent using pyridine or a trialkylamine as a catalyst to give the compounds of this invention with the corresponding alkanoyloxymethyl group of 2-7 carbon atoms, alkenoyloxymethyl group of 2-7 carbon atoms, or alkynoyloxymethyl group of 2-7 carbon atoms.
- R 1 , G 1 , G 2 , or R 4 is a halomethyl group, it can be converted to an alkoxymethyl group of 2-7 carbon atoms by displacing the halogen atom with a sodium alkoxide in an inert solvent.
- R 1 , G 1 , G 2 , or R 4 is a halomethyl group
- it can be converted to an aminomethyl group, N-alkylaminomethyl group of 2-7 carbon atoms or N,N-dialkylaminomethyl group of 3-14 carbon atoms by displacing the halogen atom with ammonia, a primary, or secondary amine, respectively, in an inert solvent.
- the chemical procedures described in the application WO-9633979 can be used to prepare the 3-cyanoquinoline intermediates used in this invention wherein R 1 , G 1 , G 2 , or R 4 are alkoxyalkylamino groups.
- the chemical procedures described in the application WO-9633978 can be used to prepare the 3-cyanoquinoline intermediates used in this invention wherein R 1 , G 1 , G 2 , or R 4 are aminoalkylamino groups.
- the chemical procedures described in the application WO-9633977 can be used to prepare the 3-cyanoquinoline intermediates used in this invention wherein R 1 , G 1 , G 2 , or R 4 are aminoalkylalkoxy groups.
- Representative compounds of this invention were evaluated in several standard pharmacological test procedures that showed that the compounds of this invention possess significant activity as inhibitors of protein tyrosine kinases, and are antiproliferative agents. Based on the activity shown in the standard pharmacological test procedures, the compounds of this invention are therefore useful as antineoplastic agents.
- the test procedures used and results obtained are shown below.
- test compounds were evaluated for their ability to inhibit the phosphorylation of the tyrosine residue of a peptide substrate catalyzed by the enzyme epidermal growth factor receptor kinase.
- the peptide substrate (RR-SRC) has the sequence arg-arg-leu-ile-glu-asp-ala-glu-tyr-ala-ala-arg-gly.
- the enzyme used in this assay is the His-tagged cytoplasmic domain of EGFR.
- a recombinant baculovirus (vHcEGFR 52 ) was constructed containing the EGFR cDNA encoding amino acids 645-1186 preceded by Met—Ala—(His) 6 .
- Sf9 cells in 100 mm plates were infected at an moi of 10 pfu/cell and cells were harvested 48 h post infection.
- a cytoplasmic extract was prepared using 1% Triton X-100 and applied to Ni-NTA column. After washing the column with 20 mM imidazole, HcEGFR was eluted with 250 mM imidazole (in 50 mM Na 2 HPO 4 , pH 8.0, 300 mM NaCl). Fractions collected were dialyzed against 10 mM HEPES, pH 7.0, 50 mM NaCl, 10% glycerol, 1 ug/mL antipain and leupeptin and 0.1 mM Pefabloc SC. The protein was frozen in dry ice/methanol and stored ⁇ 70° C.
- Test compounds were made into 10 mg/mL stock solutions in 100% dimethylsulfoxide (DMSO). Prior to experiment, stock solutions were diluted to 500 uM with 100% DMSO and then serially diluted to the desired concentration with HEPES buffer (30 mM HEPES pH 7.4).
- DMSO dimethylsulfoxide
- the inhibition data for representative compounds of the invention are shown below in TABLE 1.
- the IC 50 is the concentration of test compound needed to reduce the total amount of phosphorylated substrate by 50%.
- the % inhibition of the test compound was determined for at least three different concentrations and the IC 50 value was evaluated from the dose response curve.
- CPM(control) is in units of counts per minute and was a number expressing the amount of radiolabled ATP (g- 33 P) incorporated into the RR-SRC peptide substrate by the enzyme after 90 minutes at room temperature in the absence of test compound as measured by liquid scintillation counting.
- the CPM values were corrected for the background counts produced by ATP in the absence of the enzymatic reaction.
- the IC 50 values in TABLE 1 are averages of the individual determinations.
- a biotinylated peptide substrate is first immobilized on neutravidin-coated microtiter plates.
- the test drug the Epithelial Cell Kinase (ECK), Mg ++ , sodium vanadate (a protein tyrosine phosphatase inhibitor), and an appropriate buffer to maintain pH (7.2) are then added to the immobilized substrate-containing microtiter wells. ATP is then added to initiate phosphorylation. After incubation, the assay plates are washed with a suitable buffer leaving behind phosphorylated peptide which is exposed to horse radish peroxidase (HRP)-conjugated anti-phosphotyrosine monoclonal antibody.
- HRP horse radish peroxidase
- the antibody-treated plates are washed again and the HRP activity in individual wells is quantified as a reflection of degree of substrate phosphorylation.
- This nonradioactive format was used to identify inhibitors of ECK tyrosine kinase activity where the IC 50 is the concentration of drug that inhibits substrate phosphorylation by 50%.
- the results obtained for representative compounds of this invention are listed in TABLE 2. Multiple entries for a given compound indication it was tested multiple times.
- KDR the catalytic domain of the VEGF receptor
- KDR protein is mixed, in the presence or absence of a inhibitor compound, with a substrate peptide to be phosphorylated (a copolymer of glutamic acid and tyrosine, E:Y::4:1) and other cofactors such as Mg ++ and sodium vanadate (a protein tyrosine phosphatase inhibitor) in an appropriate buffer to maintain pH (7.2).
- a substrate peptide to be phosphorylated a copolymer of glutamic acid and tyrosine, E:Y::4:1
- other cofactors such as Mg ++ and sodium vanadate (a protein tyrosine phosphatase inhibitor)
- ATP and a radioactive tracer is then add to initiate phosphorylation.
- the radioactive phosphate associated with the acid-insoluble fraction of the assay mixture is then quantified as reflection of substrate phosphorylation.
- MAPKK mitogen activated protein
- the peptide substrates used in the assay are MBP, peptide substrate (APRTPGGRR), or synthetic Myc substrate, (KKFELLPTPPLSPSRR•5 TFA.
- the recombinant enzymes used were prepared as GST fusion proteins of human ERK 2 and human MEK 1.
- Inhibitor samples were prepared as 10 ⁇ stocks in 10% DMSO and an appropriate aliquot was used to deliver either 10 ug/ml for a single point screening dose or 100, 10, 1, and 0.1 uM final concentration for a dose response curve. Final DMSO concentrations were less than or equal to 1%.
- the reaction was run as follows in 50 mM Tris kinase buffer, pH 7.4 in a reaction volume of 50 ul. The appropriate volume of kinase buffer and inhibitor sample was added to the tube. Appropriate dilution of enzyme was delivered to give 2-5 ug recombinant MAPK (Erk) per tube. The inhibitor was incubated with MAPK (Erk) for 30 min at 0 deg. C. Recombinant Mek (MAPKK) (0.5-2.5 ug) or fully activated Mek (0.05-0.1 units) was added to activate the Erk and incubated for 30 min at 30° C.
- MAPK MAPK
- MAPKK Recombinant Mek
- MAPKK fully activated Mek
- substrate and gamma 33 P ATP was were added to give a final concentration of 0.5-1 mM MBPP or 250-500 uM Myc; 0.2-0.5 uCi gamma P 33 ATP/tube; 50 ⁇ M ATP final concentration.
- Samples were incubated at 30° C. for 30 minutes and the reaction was stopped by adding 25 ⁇ l of ice cold 10% TCA . After samples were chilled on ice for 30 min, 20 ⁇ l of sample was transferred onto P 81 phosphocellulose filter paper or appropriate MTP with embedded P 81 filter. Filter papers or MTP were washed 2 times with a large volume of 1% acetic acid, then 2 times with water.
- Samples included a positive control (activated enzyme plus substrate); a no enzyme control; a no substrate control; samples with different concentrations of putative inhibitor; and samples with reference inhibitors (other active compounds or non-specific inhibitors such as staurosporine or K252 B).
- Human tumor cell lines were plated in 96-well plates (250 ⁇ l/well, 1-6 ⁇ 10 4 cells/ml) in RPMI 1640 medium, containing 5% FBS (Fetal Bovine Serum). Twenty four hours after plating, test compounds were added at five log concentrations (0.01-100 mg/ml) or at lower concentrations for the more potent compounds. After 48 hours exposure to test compounds, cells were fixed with trichloroacetic acid, and stained with Sulforhodamine B. After washing with trichloroacetic acid, bound dye was solubilized in 10 mM Tris base and optical density was determined using plate reader. Under conditions of the assay the optical density is proportional to the number of cells in the well.
- IC 50 s concentration causing 50% inhibition of cell growth
- the test procedure is described in details by Philip Skehan et. al, J.Natl. Canc. Inst., 82, 1107-1112 (1990). These data are shown below in TABLE 3. Information about some of the cell lines used in these test procedures is available from the American Type Tissue Collection: Cell Lines and Hybridomas, 1994 Reference Guide, 8th Edition.
- mice (Charles River, Wilmington, Mass.) were used in the in vivo standard pharmacological test procedures.
- Human epidernoid carcinoma cells A-431 (American Type Culture Collection, Rockville, Md. #CRL-155) were grown in vitro as described above.
- a unit of 5 ⁇ 10 6 cells were injected SC into mice. When tumors attained a mass of between 100 and 150 mg, the mice were randomized into treatment groups (day zero). Mice were treated IP or PO once a day either on days 1, 5, and 9 or on days 1 through 10 post staging with doses of either 80, 40 or 20, or 10 mg/kg/dose of the compound to be evaluated in 0.2% Klucel. Control animals received no drug.
- Tumor mass was determined every 7 days [(length ⁇ width 2 )/2] for 28 days post staging. Relative tumor growth (Mean tumor mass on day 7, 14, 21, and 28 divided by the mean tumor mass on day zero) is determined for each treatment group.
- the % T/C (Tumor/Control) is determined by dividing the relative tumor growth of the treated group by the relative tumor growth of the placebo group and multiplying by 100. A compound is considered to be active if the % T/C is found to be significantly less than 100%.
- Example 92 The ability of the compound of Example 92 to inhibit the growth of human epidermoid tumors (A431) in vivo demonstrated below in TABLE 4 below.
- the compound of Example 92 is an effective inhibitor of tumor growth in vivo when given orally at 40 mg/Kg.
- Example 89 The ability of the compound of Example 89 to inhibit the growth of human epidermoid tumors (A431) in vivo demonstrated below in TABLE 5 below.
- Example 89 In Vivo Inhibition of the Growth of Human Epidermoid Tumors (A431) in Mice by the Compound of Example 89 a b c,d b c,d b c,d b c,d e Drug Treatment Day 7 % T/C Day 14 % T/C Day 21 % T/C Day 28 % T/C S/T mg/kg/dose 0.5% Methocel 4.18 10.44 15.08 28.23 9/10 0.4% Tween 80
- Example 89 (40 PO) 0.49 11* 0.58 6* 3.11 21* 7.20 26* 5/5
- Example 89 (10 PO) 2.09 50* 3.37 32* 5.76 38* 7.24 26* 4/5 a compound administered on days 1 through 10 PO.
- the compound of Example 89 is an effective inhibitor of tumor growth in vivo when given orally at 40 mg/Kg and 10 mg/Kg.
- the compounds of this invention are antineoplastic agents which are useful in treating, inhibiting the growth of, or eradicating neoplasms.
- the compounds of this invention are useful in treating, inhibiting the growth of, or eradicating neoplasms that express EGFR such as those of the breast, kidney, bladder, mouth, larynx, esophagus, stomach, colon, ovary, or lung.
- the compounds of this invention are useful in treating, inhibiting the growth of, or eradicating neoplasms of the breast that express the receptor protein produced by the erbB2 (Her2) oncogene.
- the compounds of this invention are also useful in the treatment of polycystic kidney disease.
- the compounds of this invention may formulated neat or may be combined with one or more pharmaceutically acceptable carriers for administration.
- pharmaceutically acceptable carriers for example, solvents, diluents and the like, and may be administered orally in such forms as tablets, capsules, dispersible powders, granules, or suspensions containing, for example, from about 0.05 to 5% of suspending agent, syrups containing, for example, from about 10 to 50% of sugar, and elixirs containing, for example, from about 20 to 50% ethanol, and the like, or parenterally in the form of sterile injectable solution or suspension containing from about 0.05 to 5% suspending agent in an isotonic medium.
- Such pharmaceutical preparations may contain, for example, from about 0.05 up to about 90% of the active ingredient in combination with the carrier, more usually between about 5% and 60% by weight.
- the effective dosage of active ingredient employed may vary depending on the particular compound employed, the mode of administration and the severity of the condition being treated. However, in general, satisfactory results are obtained when the compounds of the invention are administered at a daily dosage of from about 0.5 to about 1000 mg/kg of body weight, optionally given in divided doses two to four times a day, or in sustained release form.
- the total daily dosage is projected to be from about 1 to 1000 mg, preferably from about 2 to 500 mg.
- Dosage forms suitable for internal use comprise from about 0.5 to 1000 mg of the active compound in intimate admixture with a solid or liquid pharmaceutically acceptable carrier. This dosage regimen may be adjusted to provide the optimal therapeutic response. For example, several divided doses may be administered daily or the dose may be proportionally reduced as indicated by the exigencies of the therapeutic situation.
- the compounds of this invention may be administered orally as well as by intravenous, intramuscular, or subcutaneous routes.
- Solid carriers include starch, lactose, dicalcium phosphate, microcrystalline cellulose, sucrose and kaolin, while liquid carriers include sterile water, polyethylene glycols, non-ionic surfactants and edible oils such as corn, peanut and sesame oils, as are appropriate to the nature of the active ingredient and the particular form of administration desired.
- Adjuvants customarily employed in the preparation of pharmaceutical compositions may be advantageously included, such as flavoring agents, coloring agents, preserving agents, and antioxidants, for example, vitamin E, ascorbic acid, BHT and BHA.
- compositions from the standpoint of ease of preparation and administration are solid compositions, particularly tablets and hard-filled or liquid-filled capsules. Oral administration of the compounds is preferred.
- the compounds of this invention may also be administered parenterally or intraperitoneally.
- Solutions or suspensions of these active compounds as a free base or pharmacologically acceptable salt can be prepared in water suitably mixed with a surfactant such as hydroxy-propylcellulose.
- Dispersions can also be prepared in glycerol, liquid polyethylene glycols and mixtures thereof in oils. Under ordinary conditions of storage and use, these preparation contain a preservative to prevent the growth of microorganisms.
- the pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions.
- the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi.
- the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol and liquid polyethylene glycol), suitable mixtures thereof, and vegetable oils.
- the compounds of this invention can be administered in combination with other antitumor substances or with radiation therapy. These other substances or radiation treatments can be given at the same or at different times as the compounds of this invention. These combined therapies may effect synergy and result in improved efficacy.
- the compounds of this invention can be used in combination with mitotic inhibitors such as taxol or vinblastine, alkylating agents such as cisplatin or cyclophosamide, antimetabolites such as 5-fluorouracil or hydroxyurea, DNA intercalators such as adriamycin or bleomycin, topoisomerase inhibitors such as etoposide or camptothecin, antiangiogenic agents such as angiostatin, and antiestrogens such as tamoxifen.
- mitotic inhibitors such as taxol or vinblastine
- alkylating agents such as cisplatin or cyclophosamide
- antimetabolites such as 5-fluorouracil or hydroxyurea
- DNA intercalators such as adriamycin or bleomycin
- topoisomerase inhibitors such as etoposide or camptothecin
- antiangiogenic agents such as angiostatin
- antiestrogens such as tamoxifen
- n-Butyl lithium in hexane (96 mL, 2.5 M in n-hexane) was slowly added to 1-dimethylamino-2-propyne (20 g, 240 mmol) in 100 mL of tetrahydrofuran under nitrogen. The mixture was stirred for 1 h at ⁇ 78° C., then dry carbon dioxide was pass through overnight. The resulting solution was poured into water and washed with ethyl acetate. The aqueous layer was evaporated under reduced pressure to give the crude acid. The dry acid was dissolved in methanol, and the insoluble salt was removed via filtration. The filtrate was collected and dried in vacuo to give 15.6 g of 4-dimethylamino-but-2-ynoic acid: mass spectrum (m/e): M ⁇ H 126.
- Propargyl bromide (17.8 g, 150 mmol) was added dropwise to a mixture of bis(2-methoxy-ethyl)amine (20 g, 150 mmol) and cesium carbonate (49 g, 150 mmol) in 350 mL of acetone. The mixture was stirred overnight under nitrogen at room temperature. The inorganic salts were then filtered off, and the solvent was removed. The residue was dissolved in saturated sodium bicarbonate solution and extracted with ethyl acetate. The organic extracts were then evaporated to give 20 g of bis-(2-methoxy-ethyl)-prop-2-ynyl-amine: mass spectrum (m/e): M+H 172.
- Propargyl bromide (26.8 g, 225 mmol) was added dropwise to a mixture of N-(2-methoxyethyl)methyl amine (20 g, 225 mmol) and cesium carbonate (73 g, 225 mmol) in 350 mL of acetone. The mixture was stirred overnight under nitrogen at room temperature. The inorganic salts were then filtered off, and the solvent was removed. The residue was dissolved in saturated sodium bicarbonate solution and extracted with ethyl acetate. The organic extracts were then evaporated to give 14 g of (2-methoxy-ethyl)-methyl-prop-2-ynyl-amine: mass spectrum (m/e): M+H 127.
- Propargyl bromide (33.4 g, 281 mmol) was added dropwise to a mixture of isopropyl-methyl-amine (20 g, 281 mmol) and cesium carbonate (90 g, 281 mmol) in 350 mL of acetone. The mixture was stirred overnight under nitrogen at room temperature. The inorganic salts were then filtered off, and the solvent was removed. The residue was dissolved in saturated sodium bicarbonate solution and extracted with ethyl acetate. The organic extracts were then evaporated to give 4.6 g of allyl-methyl-prop-2-ynyl-amine: mass spectrum (m/e): M+H 110.
- n-Butyl lithium in hexane (16.4 mL, 2.5M in n-hexane) was slowly added to allyl-methyl-prop-2-ynyl-amine (4.5 g, 46 mmol) in 50 mL of tetrahydrofuran under nitrogen.
- the mixture was stirred for 1 hr at ⁇ 78° C., then dry carbon dioxide was passed through overnight.
- the resulting solution was poured into water and washed with ethyl acetate.
- the aqueous layer was evaporated under reduced pressure to give the crude acid.
- the dry acid was dissolved in methanol, and the insoluble salt was removed via filtration.
- the filtrate was collected and dried in vacuo to give 4.1 g of 4-(allyl-methyl-amino)-but-2-ynoic acid: mass spectrum (m/e): M ⁇ H 152.
- n-Butyllithium in hexane was added dropwise to a solution of 10.1 g (55.8 mmol) of 3-(1,4-dioxa-8-azaspiro[4,5]dec-8-yl)but-2-yne in 185 mL of THF at ⁇ 78° C. under N 2 . After stirring at ⁇ 78° C. for 1 h, CO 2 was bubbled into the solution as it slowly came to 25° C. After stirring overnight, the reaction was diluted with 150 mL of water, extracted with ethyl acetate and the extracts were discarded. The solution was adjusted to pH 6 with 2 M sulfuric acid and evaporated.
- the mixture was concentrated down to 1 ml and purified by silica gel chromatography, eluting with a solvent gradient of 1 to 2 percent methanol/methylene chloride, to provide 0.090 g of 4-chloro-6-methoxy-7-(3-pyridin-4-yl-propoxy)-quinoline-3-carbonitrile as an off-white gum.
- Example 103 4-bromo-but-2-enoic acid[4-(3-chloro-4-fluoro-phenylamino)-3-cyano-7-methoxy-quinolin-6-yl]-amide and bis-(2-methoxy-ethyl)-amine was converted to 52.3 mg of the title compound as the bis-trifluoroacetate salt mass spectrum (electrospray, m/e): M+H 542.0.
- Example 103 4-bromo-but-2-enoic acid[4-(3-chloro-4-fluoro-phenylamino)-3-cyano-7-methoxy-quinolin-6-yl]-amide and bis-(2-hydroxy-ethyl) amine was converted to 22.2 mg of the title compound (free base), mass spectrum (electrospray, m/e): M+H 514.0 and 60.7 mg of the title compound as the bis-trifluoroacetate salt); mass spectrum (electrospray, m/e): M+H 514.0.
- Example 103 4-bromo-but-2-enoic acid[4-(3-chloro-4-fluoro-phenylamino)-3-cyano-7-methoxy-quinolin-6-yl]-amide and thiomorpholine was converted to 48.1 mg of the title compound (free base), mass spectrum (electrospray, m/e): M+H 512.0 and 33.2 mg of the title compound as the bis-trifluoroacetate salt); mass spectrum (electrospray, m/e): M+H 512.0.
- Example 103 4-bromo-but-2-enoic acid[4-(3-chloro-4-fluoro-phenylamino)-3-cyano-7-methoxy-quinolin-6-yl]-amide and 1,4,7-trioxa-10-aza cyclododecane was converted to 37.5 mg of the title compound(free base) and mass spectrum (electrospray, m/e): M+H 584.1, 17.1 mg of the title compound as the bis-trifluoroacetate salt); mass spectrum (electrospray, m/e): M+H 584.1.
- Example 117 4-bromo-but-2-enoic acid[4-(3-chloro-4-fluoro-phenylamino)-3-cyano-7-methoxy-quinolin-6-yl]-amide. (0.51 mmol.) was reacted with 2,5-dimethylpyrrolidine (1.02 mmol., 101 mg.) in dimethylformamide. The crude product was also purified via chromatography as Example 117, leaving 214 mg. (82%) of the yellow product: mp 110-113° C.
- Example 117 4-bromo-but-2-enoic acid[4-(3-chloro-4-fluoro-phenylamino)-3-cyano-7-methoxy-quinolin-6-yl]-amide. (0.51 mmol.) was stirred in dimethylformamide with 4-piperidone monohydrate hydrochloride (470 mg., 3.06 mmol.), and sodium bicarbonate (386 mg., 4.59 mmol.), for 24 hours. The crude product was purified in the same manner as Example 117 and produced 192 mg. (72%) of the product as a yellow solid: mp 225-30° C.
- a more polar component (0.54 g) was 4-(3-chloro-4-fluoro-phenylamino)-7-methoxy-6-(4-morpholin-4-yl-butylamino)-quinoline-3-carbonitrile; a less polar component (0.28 g) is the compound of this invention, 4-(3-chloro-4-fluoro-phenylamino)-7-methoxy-6-pyrrolidin-l-yl-quinoline-3-carbonitrile, obtained as a yellow solid: mass spectrum electrospray, m/e): M+H 397.4.
- Example 23 4-(3-chloro-4-fluoroanilino)-7-(4-methyl-1-piperazinyl)-6-nitro-3-quinolinecarbonitrile was reduced with iron powder and acetic acid in MeOH to give the title compound as an amorphous solid; ms 411.2 (M+H) + , 206.2 (M+2H) +2 .
Abstract
Description
-
- X is cycloalkyl of 3 to 7 carbon atoms, which may be optionally substituted with one or more alkyl of 1 to 6 carbon atom groups; or is a pyridinyl, pyrimidinyl, or phenyl ring wherein the pyridinyl, pyrimidinyl, or phenyl ring may be optionally mono- di-, or tri-substituted with a substituent selected from the group consisting of halogen, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, azido, hydroxyalkyl of 1-6 carbon atoms, halomethyl, alkoxymethyl of 2-7 carbon atoms, alkanoyloxymethyl of 2-7 carbon atoms, alkoxy of 1-6 carbon atoms, alkylthio of 1-6 carbon atoms, hydroxy, trifluoromethyl, cyano, nitro, carboxy, carboalkoxy of 2-7 carbon atoms, carboalkyl of 2-7 carbon atoms, phenoxy, phenyl, thiophenoxy, benzoyl, benzyl, amino, alkylamino of 1-6 carbon atoms, dialkylamino of 2 to 12 carbon atoms, phenylamino, benzylarnino, alkanoylamino of 1-6 carbon atoms, alkenoylarnino of 3-8 carbon atoms, alkynoylamino of 3-8 carbon atoms, carboxyalkyl of 2-7 carbon atoms, carboalkoxyalky of 3-8 carbon atoms, aminoalkyl of 1-5 carbon atoms, N-alkylaminoalkyl of 2-9 carbon atoms, N,N-dialkylaminoalkyl of 3-10 carbon atoms, N-alkylaminoalkoxy of 2-9 carbon atoms, N,N-dialkylaminoalkoxy of 3-10 carbon atoms, mercapto, and benzoylamino;
- Z is —NH—, —O—, —S—, or —NR—;
- R is alkyl of 1-6 carbon atoms, or carboalkyl of 2-7 carbon atoms;
- G1, G2, R1, and R4 are each, independently, hydrogen, halogen, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, alkenyloxy of 2-6 carbon atoms, alkynyloxy of 2-6 carbon atoms, hydroxymethyl, halomethyl, alkanoyloxy of 1-6 carbon atoms, alkenoyloxy of 3-8 carbon atoms, alkynoyloxy of 3-8 carbon atoms, alkanoyloxymethyl of 2-7 carbon atoms, alkenoyloxymethyl of 4-9 carbon atoms, alkynoyloxymethyl of 4-9 carbon atoms, alkoxymethyl of 2-7 carbon atoms, alkoxy of 1-6 carbon atoms, alkylthio of 1-6 carbon atoms, alkylsulphinyl of 1-6 carbon atoms, alkylsulphonyl of 1-6 carbon atoms, alkylsulfonamido of 1-6 carbon atoms, alkenylsulfonamido of 2-6 carbon atoms, alkynylsulfonamido of 2-6 carbon atoms, hydroxy, trifluoromethyl, trifluoromethoxy, cyano, nitro, carboxy, carboalkoxy of 2-7 carbon atoms, carboalkyl of 2-7 carbon atoms, phenoxy, phenyl, thiophenoxy, benzyl, amino, hydroxyamino, alkoxyamino of 1-4 carbon atoms, alkylamino of 1-6 carbon atoms, dialkylamino of 2 to 12 carbon atoms, N-alkylcarbamoyl, N,N-dialkylcarbamoyl, N-alkyl-N-alkenylamino of 4 to 12 carbon atoms, N,N-dialkenylamino of 6-12 carbon atoms, phenylamino, benzylamino,
-
- R8R9—CH—M—(C(R6)2)k—Y—, R7—(C(R6)2)g—Y—, R7—(C(R6)2)p—M—(C(R6)2)k—Y—, or Het-(C (R6)2)q—W—(C(R6)2)k—Y— with the proviso that either G1 or G2 or both G1 and G2 must be a radical selected from the group
-
- R8R9—CH—M—(C(R6)2)k—Y—, R′7—(C(R6)2)g—Y—, R7—(C(R6)2)p—M—(C(R6)2)k—Y—, Het-(C (R6)2)q—W—(C(R6)2)k—Y—, or
-
- Y is a divalent radical selected from the group consisting of
-
- R7 is —NR6R6, —J, —OR6, —N(R6)3 +, or —NR6(OR6);
- R′7 is —NR6(OR6), —N(R6)3 +, alkenoxy of 1-6 carbon atoms, alkynoxy of 1-6 carbon atoms, alkynoxy of 1-6 carbon atoms, N-alkyl-N-alkenylamino of 4 to 12 carbon atoms, N,N-dialkenylamino of 6-12 carbon atoms, N-alkyl-N-alkynylamino of 4 to 12 carbon atoms, N-alkenyl-N-alkynylamino of 4 to 12 carbon atoms, or N,N-dialkynylamino of 6-12 carbon atoms with the proviso that the alkenyl or alkynyl moiety is bound to a nitrogen or oxygen atom through a saturated carbon atom;
- M is >NR6, —O—, >N—(C(R6)2)pNR6R6, or >N—(C (R6)2)p—OR6;
- W is >NR6, —O— or is a bond;
- Het is a heterocycle selected from the group consisting of morpholine, thiomorpholine, thiomorpholine S-oxide, thiomorpholine S,S-dioxide, piperidine, pyrrolidine, aziridine, pyridine, imidazole, 1,2,3-triazole, 1,2,4-triazole, thiazole, thiazolidine, tetrazole, piperazine, furan, thiophene, tetrahydrothiophene, tetrahydrofuran, dioxane, 1,3-dioxolane tetrahydropyran, and
-
- wherein the heterocycle is optionally mono- or di-substituted on carbon or nitrogen with R6, optionally mono- or di-substituted on carbon with hydroxy, —N(R6)2, or —OR6, optionally mono or di-substituted on carbon with the mono-valent radicals —(C(R6)2)s OR6 or —(C(R6)2)sN(R6)2, or optionally mono or di-substituted on a saturated carbon with divalent radicals —O— or —O(C(R6)2)sO—;
- R6 is hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, cycloalkyl of 1-6 carbon atoms, carboalkyl of 2-7 carbon atoms, carboxyalkyl (2-7 carbon atoms), phenyl, or phenyl optionally substituted with one or more halogen, alkoxy of 1-6 carbon atoms, trifluoromethyl, amino, alkylamino of 1-3 carbon atoms, dialkylamino of 2-6 carbon atoms, nitro, cyano, azido, halomethyl, alkoxymethyl of 2-7 carbon atoms, alkanoyloxyniethyl of 2-7 carbon atoms, alkylthio of 1-6 carbon atoms, hydroxy, carboxyl, carboalkoxy of 2-7 carbon atoms, phenoxy, phenyl, thiophenoxy, benzoyl, benzyl, phenylamino, benzylamino, alkanoylamino of 1-6 carbon atoms, or alkyl of 1-6 carbon atoms;
- R2, is selected from the group consisting of
-
- R3 is independently hydrogen, alkyl of 1-6 carbon atoms, carboxy, carboalkoxy of 1-6 carbon atoms, phenyl, carboalkyl of 2-7 carbon atoms,
-
- R7—(C(R6)2)s—, R7—(C(R6)2)p—M—(C(R6)2)r—, R8R9—CH—M—(C(R6)2)r—, or Het-(C(R6)2)q—W—(C(R6)2)r—;
- with the proviso that at least one of the R3 groups is selected from the group
-
- R′7—(C(R6)2)s—, R7—(C(R6)2)p—M—(C(R6)2)r—, R8R9—CH—M—(C(R6)2)r—, or Het-(C(R6)2)q—W—(C(R6)2)r—;
- R5 is independently hydrogen, alkyl of 1-6 carbon atoms, carboxy, carboalkoxy of 1-6 carbon atoms, phenyl, carboalkyl of 2-7 carbon atoms,
-
- R7—(C(R6)2)s—, R7—(C(R6)2)p—M—(C(R6)2)r—, R8R9—CH—M—(C(R6)2)r—, or Het-(C(R6)2)q—W—(C(R6)2)r—;
- R8, and R9 are each, independently, —(C(R6)2)rNR6R6, or —(C(R6)2)rOR6;
- J is independently hydrogen, chlorine, fluorine, or bromine;
- Q is alkyl of 1-6 carbon atoms or hydrogen;
- a=0 or 1;
- g=1-6;
- k=0-4;
- n is 0-1;
- p=2-4;
- q=0-4;
- r=1-4;
- s=1-6;
- u=0-4 and v=0-4, wherein the sum of u+v is 2-4;
- or a pharmaceutically acceptable salt thereof,
- provided that
- when R6 is alkenyl of 2-7 carbon atoms or alkynyl of 2-7 carbon atoms, such alkenyl or alkynyl moiety is bound to a nitrogen or oxygen atom through a saturated carbon atom;
- and further provided that
- when Y is —NR6— and R7 is —NR6R6, —N(R6)3 +, or —NR6(OR6), then g=2-6;
- when M is —O— and R7 is —OR6, then p=1-4;
- when Y is —NR6—, then k=2-4;
- when Y is —O— and M or W is —O—, then k=1-4;
- when W is not a bond with Het bonded through a nitrogen atom, then q=2-4;
- and when W is a bond with Het bonded through a nitrogen atom and Y is —O— or —NR6—, then k=2-4.
Sarges, Reinhard; Gallagher, Andrea; Chambers, Timothy J.; Yeh, Li An, J. Med. Chem., 36, 2828 (1993); Savini, Luisa; Massarelli, Paola; Pellerano, Cesare; Bruni, Giancarlo, Farmaco, 48(6), 805 (1993); Ife, Robert J.; Brown, Thomas H.; Keeling, David J.; Leach, Colin, J. Med. Chem., 35, 3413 (1992); Hanifin, J. William; Capuzzi, Rosemary; Cohen, Elliott, J. Med. Chem., 12(5), 1096 (1969); Marecki, Paul E.; Bambury, Ronald E., J. Pharm. Sci., 73(8), 1141 (1984); Pellerano, C.; Savini, L.; Massarelli, P.; Bruni, G.; Fiaschi, A. I., Farmaco, 45(3), 269, (1990); Marecki, Paul E.; Bambury, Ronald E., J. Pharm. Sci., 73(8), 114 (1984); patent application WO 8908105; U.S. Pat. No. 4,343,804; U.S. Pat. No. 3,470,186.
The preparation of the compounds of this invention encompassed by Formula 12 is described below in Flowsheet 2 where X, Z, n, R1, G2, G1, and R4 are as described above. The substituted aniline of Formula 6 is heated with or without a solvent with the reagent 7 to give intermediate 8 as a mixture of isomers. Thermolysis of 8 in a high boiling solvent such as diphenyl ether at 200-350° C. gives the 3-cyano quinolones of Formula 9; these intermediates may also exist in the 4-hydroxy quinoline tautomeric form. In those cases where R4 is a hydrogen atom, the intermediates 9 may be formed as a mixture of two regioisomers. These isomers can be separated by methods well known in the art including, but not limited to, fractional crystallization and chromatographic methods. The separated isomers can then be converted separately to the compounds of the invention. Alternatively, the isomers can be separated at a later stage of the synthesis. Heating compounds 9 with or without solvent with a chlorinating agent such as phosphorous oxychloride or phosphorous pentachloride gives the 4-chloro-3-cyano quinolines of Formula 10. Condensation of 10 with a nucleophilic amine, aniline, mercaptan, thiophenol, phenol, or alcohol reagent of Formula 11 gives the 3-cyano quinolines intermediates of Formula 12; this condensation can be accelerated by heating the reaction mixture or by using basic catalysts such as trialkylamines, sodium hydride in an inert solvent, sodium or potassium alkoxides in an alcohol solvents, and the like. In those cases where the substituents may contribute an asymmetric carbon atom, the intermediates can be used as the racemate or as the individual R or S entantiomers in which case the compounds of this invention will be in the racemic or R and S optically active forms, respectively. In cases where the substituents may contribute more than one asymmetric carbon atoms, diasteriomers may be present; these can be separated by methods well known in the art including, but not limited to, fractional crystallization and chromatographic methods. In those cases where R1, G2, G1, and R4 moieties contain primary or secondary amino groups, the amino groups may first have to be used in protected form prior to reaction with reagent 7. Suitable protecting groups include, but are not limited to, tert-butoxycarbonyl (BOC) and benzyloxycarbonyl (CBZ) protecting groups. The former protecting group can be removed from the final products of Formula 12 by treatment with an acid such as trifluoroactic acid while the latter protecting group can be removed by catalytic hydrogenation. In those cases where the R1, G2, G1, and R4 moieties contain hydroxyl groups, the hydroxyl groups may first have to be used in protected form prior to reaction with reagent 7. Suitable protecting groups include, but are not limited to, t-butyldimethylsilyl, tetrahydropyranyl, or benzyl protecting groups. The first two protecting groups can be removed from the final products of formula 12 by treatment with an acid such as acetic acid or hydrochloric acid while the latter protecting group can be removed by catalytic hydrogenation.
The preparation of the compounds of this invention encompassed by Formula 24 is described below in Flowsheet 4 wherein R1, G2, R4, Z, n, and X are defined. R10 is alkyl of 1-6 carbon atoms (preferably isobutyl). R2′ is a radical selected from the group consisting of:
wherein R6, R3, R5, J, s, r, u, and v are defined. According to the reactions outlined in Flowsheet 4, a 4-chloro-3-cyano-6-nitroquinoline, 16, can be reacted with an amine or aniline 17 by heating in an inert solvent such as tetrahydrofuran, butanol, or methoxyethanol to give compounds of Formula 20 where Z is —NH—. The reaction of 16 with a mercaptan or thiophenol 18 in an inert solvent can be accomplished using a base such as sodium hydride to give compounds of Formula 20 where Z is —S—. The reaction of 16 with a alcohol or phenol 19 in an inert solvent can be accomplished using a base such as sodium hydride to give compounds of Formula 20 where Z is —O—. Compounds of Formula 20 can be reduced to a 6-amino-3-cyano-quinoline, 21, using a reducing agent such as sodium hydrosulfite in a two phase system consisting of tetrahydrofuran and water in the presence of a small amount of phase transfer catalyst or by using iron in refluxing protic solvents containing acetic acid or ammonium chloride. Acylation of 21 with either an acid chloride of Formula 22 or a mixed anhydride of Formula 23 (which is prepared from the corresponding carboxylic acid) in an inert solvent such as tetrahydrofuran (THF) in the presence of an organic base such as pyridine, triethylamine, diisopropylethylamine, or N-methyl morpholine gives the compounds of this invention of Formula 24. In those cases where 22 or 23 have an asymmetric carbon atom, they can be used as the racemate or as the individual R or S entantiomers in which case the compounds of this invention will be in the racemic or R and S optically active forms, respectively. In those cases, where the R2′ contains primary or secondary amino groups, the amino groups will first have to be protected prior to anhydride or acid chloride formation. Suitable protecting groups include, but are not limited to, tert-butoxycarbonyl (BOC) and benzyloxycarbonyl (CBZ) protecting groups. The former protecting group can be removed from the final products of Formula 24 by treatment with an acid such as trifluoroactic acid while the latter protecting group can be removed by catalytic hydrogenation. In those cases where the R2′ contains hydroxyl groups, the hydroxyl groups may first have to be protected prior to anhydride or acid chloride formation. Suitable protecting groups include, but are not limited to, t-butyldimethylsilyl, tetrahydropyranyl, or benzyl protecting groups. The first two protecting groups can be removed from the final products of Formula 24 by treatment with an acid such as acetic acid or hydrochloric acid while the latter protecting group can be removed by catalytic hydrogenation. In those cases, in intermediates 17, 18, or 19 where X contains primary or secondary amino groups or hydroxyl groups, it may be necessary to protect these groups prior to the reaction with 16. The same amine or alcohol protecting groups describe above can be used and they can be removed from the products 24 as previously described.
By using methods similar to that describe above in Flowsheet 4, the intermediates 25 can be converted to the compounds of this invention, 26.
In order to prepare the compounds of this invention, certain amines are required. Some representative amines are shown below in List A wherein R6, p, and r are as defined above. These amines are available commercially, are known in the chemical literature, or can be prepared by simple procedures that are well known in the art. In some cases, these amines may have an asymmetric carbon atoms; they can be used as the racemate or they can be resolved and used as the individual R or S entantiomers in which case the compounds of this invention will be in the racemic or optically active forms, respectively. Throughout this application in the Flowsheets shown below, these amines, and other similar amines, will be represented by the generic structure of the formula:
Other carboxylic acid chlorides and anhydrides needed to prepare some of the compounds of this invention are prepared as shown below in Flowsheet 8 wherein R6, R3, R10, X, Z, J′, n, and s are as defined above. Q′ is an alkyl group of 1-6 carbon atoms. The esters 49, 53, or 57 can be hydrolyzed with a base such as barium hydroxide to give the respective carboxylic acid 50, 54, or 58. These acid can be converted to the respective carboxylic acid chlorides 51 or 56 by using oxalyl chloride and catalytic N,N-dimethylforrnamide in an inert solvent or respective mixed anhydrides 55 or 59 by using isobutyl chloroformate and an organic base such as N-methylmorpholine. The leaving group in compounds represented by Formula 52 can be displaced by the amines of List A or the alcohols of List B by using procedures previously described to give the intermediates 57 and 53, respectively. These carboxylic acid chlorides 51 and 56 and these anhydrides 55 and 59 can be used to prepare some of the compounds of this invention by using the methods outlined herein above in the Flowsheets.
and A is the radical:
—N(R′)2, —OR′, or −J′
wherein —N(R′)2 is derived from the amines of List A, —OR′ are derived from the alcohols of List B, and J′ is a leaving group as defined previously. By making use of these carboxylic acid chlorides and anhydrides, by following the methods summarized in the above in Flowsheets, and by pursuing the details described in the examples given below, many of the compounds of this invention can be prepared.
By applying the methods summarized above, 61b can be converted to 63b and 64b via the intermediate 62b.
Refluxing 73 and 74 in an a solvent such as ethanol gives the intermediate 75 which can react with an amine in refluxing ethanol to give the compounds of this invention represented by Formula 76. Treating 75 with an excess of a sodium alkoxide in an inert solvent or a solvent from which the alkoxide is derived gives the compounds of this invention of Formula 77.
TABLE A | |||
Reagent | Final | 100 Rxns | |
1M HEPES (pH 7.4) | 12.5 | mM | 50 | μL | |
10 mM Na3VO4 | 50 | uM | 20 | μL | |
1M MnCl2 | 10 | mM | 40 | μL | |
1 mM ATP | 20 | uM | 80 | μL | |
33P-ATP | 2.5 | uCi | 25 | μL | |
% inhibition=100−[CPM(drug)/CPM(control)]×100
where CPM(drug) is in units of counts per minute and is a number expressing the amount of radiolabled ATP (g-33P) incorporated onto the RR-SRC peptide substrate by the enzyme after 90 minutes at room temperature in the presence of test compound as measured by liquid scintillation counting. CPM(control) is in units of counts per minute and was a number expressing the amount of radiolabled ATP (g-33P) incorporated into the RR-SRC peptide substrate by the enzyme after 90 minutes at room temperature in the absence of test compound as measured by liquid scintillation counting. The CPM values were corrected for the background counts produced by ATP in the absence of the enzymatic reaction. The IC50 values in TABLE 1 are averages of the individual determinations.
TABLE 1 |
(recombinant enzyme) |
Inhibition of Epidermal Growth Factor Receptor Kinase |
IC50 | Number of | |
Compound | (μM) | Tests |
72 | 0.006 | 1 |
74 | 0.01 | 1 |
75 | 0.0004 | 2 |
76 | 0.01 | 2 |
77 | 0.006 | 1 |
79 | 0.00036 | 3 |
82 | 0.05 | 1 |
93 | 1.0 | 1 |
95 | 0.005 | 1 |
96 | 0.1 | 1 |
108 | 0.026 | 2 |
106 | 0.013 | 2 |
107 | 0.5 | 1 |
109 | 0.007 | 2 |
89 | 0.01 | 1 |
115 | 0.005 | 1 |
91 | 0.015 | 1 |
119 | 0.00005 | 1 |
103 | 0.008 | 2 |
TABLE 2 |
Inhibition of Kinase insert Domain containing Receptor (KDR), |
Epithelial Cell Kinase (Eck), and Mitogen Activated Protein |
Kinase (Mek-Erk) |
VEGF | Eck | Mek and Erk | erbB2 % Inh | |
Example | μM | μM | μM | 2 μg/mL |
72 | >41.724 | >100 | 96 | |
74 | >42.982 | >100 | 95 | |
75 | >37.284 | 100 | ||
76 | >40.617 | >100 | 96 | |
77 | 42.162 | >100 | 105 | |
78 | >21.269 | 40 | 53 | |
79 | >38.610 | 80 | ||
82 | >1.8315 | >1.832 | 30 | |
85 | >21.584 | 10 | 87 | |
4 | ||||
1.8 | ||||
1.8 | ||||
TABLE 3 |
Inhibition of Cancer Cell Growth as |
Measured by Cell Number (IC50 μg/mL) |
Exam- | ||||||
ple | MDAMB435 | SW620 | A431 | SKBR3 | 3T3 | Her2/3T3 |
85 | 27.6 | 17.98 | 4.91 | 1.74 | ||
75 | 0.2 | 0.5 | 0.1 | 0.04 | ||
74 | 3.9 | 0.6 | 0.9 | 1.0 | ||
72 | 3.5 | 0.4 | 0.9 | 0.8 | ||
77 | 0.1 | 0.1 | 0.03 | 0.02 | ||
79 | 0.3 | 0.1 | 0.04 | 0.01 | ||
76 | 0.284 | 0.239 | 0.050 | 0.031 | ||
78 | 3.194 | >5 | 0.369 | 1.495 | ||
91 | 1.83 | 1.73 | 0.232 | 0.181 | 2.87 | 0.375 |
89 | 2.07 | 1.53 | 0.245 | 0.107 | 2.04 | 0.192 |
90 | 1.74 | 1.24 | 0.234 | 0.148 | 2.1 | 0.329 |
92 | 3.32 | 2.51 | 0.283 | 0.188 | 2.79 | 0.35 |
TABLE 4 |
In Vivo Inhibition of the Growth of Human Epidermoid Tumors (A431) in Mice |
by the Compound of Example 92 |
a | b | c,d | b | c,d | b | c,d | b | c,d | e |
Drug Treatment | Day 7 | % T/C | Day 14 | % T/C | Day 20 | % T/C | Day 28 | % T/C | S/T |
mg/kg/dose | |||||||||
0.5% Methocel | |||||||||
0.4% Tween 80 | 5.51 | 10.43 | 12.36 | 14.18 | 10/10 | ||||
Example 92 (40 PO) | 1.49 | 27* | 1.58 | 15* | 2.60 | 21* | 6.22 | 44 | 5/5 |
Example 92 (10 PO) | 3.94 | 72 | 10.41 | 100 | 14.76 | 119 | 22.51 | 159 | 5/5 |
a compound administered on days 1 through 10 PO. | |||||||||
|
|||||||||
*Indicates statistically (p <0.01) significant reduction in Relative Tumor Growth of Treated Group compared to the Placebo Control. | |||||||||
e S/T = # of Survivors/# of Treated on Day +28 post tumor staging. |
TABLE 5 |
In Vivo Inhibition of the Growth of Human Epidermoid Tumors (A431) in Mice |
by the Compound of Example 89 |
a | b | c,d | b | c,d | b | c,d | b | c,d | e |
Drug Treatment | Day 7 | % T/C | Day 14 | % T/C | Day 21 | % T/C | Day 28 | % T/C | S/T |
mg/kg/dose | |||||||||
0.5% Methocel | 4.18 | 10.44 | 15.08 | 28.23 | 9/10 | ||||
0.4% Tween 80 | |||||||||
Example 89 (40 PO) | 0.49 | 11* | 0.58 | 6* | 3.11 | 21* | 7.20 | 26* | 5/5 |
Example 89 (10 PO) | 2.09 | 50* | 3.37 | 32* | 5.76 | 38* | 7.24 | 26* | 4/5 |
a compound administered on days 1 through 10 PO. | |||||||||
|
|||||||||
*Indicates statistically (p <0.01) significant reduction in Relative Tumor Growth of Treated Group compared to the Placebo Control. | |||||||||
e S/T = # of Survivors/# of Treated on Day +28 post tumor staging. |
TABLE 6 | |||
Ex- | |||
am- | m.p. | mass | |
ple | Compound | (° C.) | spectrum |
137 | 4-[(2-Methoxy-ethyl)-methyl-amino]- | amorphous | 538.0 |
but-2-enoic acid [4-(3-bromo-phenyl- | (M + H) | ||
amino)-3-cyano-7-ethoxy-quinolin-6- | |||
yl]-amide | |||
138 | 4-(2,4-Dichloro-5-methoxy- | 122-125 | 531.0 |
phenylamino)-7-[3-(4-hydroxy- | (M + H) | ||
piperidin-1-yl)-propoxy]-6-methoxy- | |||
quinoline-3-carbonitrile | |||
139 | 4-(2,4-Dichloro-5-methoxy- | 133-137 | 560.1 |
phenylamino)-7-{3-[4-(2-hydroxy- | (M + H) | ||
ethyl)-piperazin-1-yl]-propoxy}-6- | |||
methoxy-quinoline-3-carbonitrile | |||
140 | 4-(2-Bromo-4-chloro-phenylamino)- | 186-188 | 597.0 |
7-{2-[(2-hydroxy-ethyl-methyl-amino]- | (M + H), | ||
ethoxy}-6-methoxy-quinoline-3- | 254.2 | ||
carbonitrile | (M + 2H)+2 | ||
141 | 4-(2,4-Dichloro-5-methoxy- | 129-131 | 533.0 |
phenylamino)-7-{3-[(2-hydroxy-ethyl)- | (M + H) | ||
methyl-amino]-propoxy}-6-methoxy- | |||
quinoline-3-carbonitrile | |||
142 | 4-(2,4-Dichloro-5-methoxy- | 116-118 | 505.2 |
phenylamino)-6-methoxy-7-(3- | (M + H) | ||
thiomorpholin-4-yl-propoxy)-quinoline- | |||
3-carbonitrile | |||
143 | 4-(2,4-Dichloro-5-methoxy- | 98-102 | 529.2 |
phenylamino)-6-methoxy-7-[3-(2- | (M + H) | ||
methoxy-ethylamino)-propoxy]- | |||
quinoline-3-carbonitrile | |||
144 | 4-(2,4-Dichloro-5-methoxy- | 114-117 | 587.2 |
phenylamino)-6-methoxy-7-[3-(4- | (M + H) | ||
methyl-piperidin-1-yl)-propoxy]- | |||
quinoline-3-carbonitrile | |||
145 | 4-(2,4-Dichloro-5-methoxy- | 155-157 | 545.3 |
phenylamino)-7-[3-(2,6-dimethyl- | (M + H) | ||
morpholin-4-yl)-propoxy]-6-methoxy- | |||
quinoline-3-carbonitrile | |||
146 | 4-(2-Bromo-4-chloro-phenylamino)-7- | 156-158 | 562.1 |
{2-[4-(2-hydroxy-ethyl)-piperazin-1- | (M + H) | ||
yl]-ethoxy}-6-methoxy-quinoline-3- | 281.7 | ||
carbonitrile | (M + 2H)+2 | ||
147 | 4-(2-Bromo-4-chloro-phenylamino)- | 165-167 | 533.1 |
7-[2-(4-hydroxy-piperidin-1-yl)- | (M + H) | ||
ethoxy]-6-methoxy-quinoline-3- | 267.1 | ||
carbonitrile | (M + 2H)+2 | ||
148 | 4-(2-Bromo-4-chloro-phenylamino)-6- | 164-166 | 533.0 |
methoxy-7-(2-thiomorpholin-4-yl- | (M + H) | ||
ethoxy)-quinoline-3-carbonitrile | 268.1 | ||
(M + 2H)+2 | |||
149 | 4-(2,4-Dichloro-5-methoxy- | 115-120 | 529.2 |
phenylamino)-7-[3-(2,5-dimethyl- | (M + H) | ||
pyrrolidin-1-yl)-propoxy]-6-methoxy- | |||
quinoline-3-carbonitrile | |||
150 | 4-(2,4-Dichloro-5-methoxy- | 142-147 | 505.2 |
phenylamino)-7-[3-(3-hydroxy- | (M + H) | ||
propylamino)-propoxy]-6-methoxy- | |||
quinoline-3-carbonitrile | |||
151 | 1-{3[3-Cyano-4-(2,4-dichloro-5- | 95-101 | 587.2 |
methoxy-phenylamino)-6-methoxy- | (M + H) | ||
quinolin-7-yloxy]-propyl}-piperidine-4- | |||
carboxylic acid ethyl ester | |||
152 | 7-[3-(4-acetyl-1-piperazinyl)propoxy]-4- | 115-118 | 558.2 |
[(2,4-dichloro-5-methoxyphenyl)amino]- | (M + H) | ||
6-methoxy-3-quinolinecarbonitrile | |||
153 | 4-(3-chloro-4-fluoroanilino)-7- | 413.2 | |
methyoxy-6(4-morpholinyl)-3- | (M + H) | ||
quinolinecarbonitrile | |||
154 | 7-[3-(4-Benzyl-piperazin-1-yl)- | 140-142 | 606.2 |
propoxy]-4-(2,4-dichloro-5-methoxy- | (M + H) | ||
phenylamino)-6-methoxy-quinoline-3- | |||
carbonitrile | |||
155 | 4-(2,4-Dichloro-5-methoxy- | 161-164 | 491.1 |
phenylamino)-7-[3-(2-hydroxy- | (M + H) | ||
ethylamino)-propoxy]-6-methoxy- | |||
quinoline-3-carbonitrile | |||
156 | 4-(2,4-Dichloro-5-methoxy- | 162-165 | 519.2 |
phenylamino)-7-{3-[ethyl-(2-hydroxy- | (M + H) | ||
ethyl)-amino]-propoxy}-6-methoxy- | |||
quinoline-3-carbonitrile | |||
157 | 7-{3-[Bis(2-methoxy-ethyl)-amino]- | 112-113 | 563.1 |
propoxy}-4-(2,4-dichloro-5-methoxy- | (M + H) | ||
phenylamino)-6-methoxy-quinoline-3- | |||
carbonitrile | |||
158 | 7-{3-[Bis(2-hydroxy-ethyl)-amino]- | 156-159 | 535.1 |
propoxy}-4-(2,4-dichloro-5-methoxy- | (M + H) | ||
phenylamino)-6-methoxy-quinoline-3- | |||
carbonitrile | |||
159 | 4-(3-chloro-4-fluoroanilino)-7-(4- | 235-239 | 428.1 |
morpholinyl)-6-nitro-3-quinoline- | (M + H) | ||
carbonitrile | |||
160 | N-[4-(3-chloro-4-fluoroanilino)-3-cyano- | 260-266d | 464.1 |
7-(4-morpholinyl)-6-quinolinyl]-2- | (M + H) | ||
butynamide | |||
161 | 6-amino-4-(3-chloro-4-fluoroanilino)-7- | amorphous | 398.2 |
(4-morpholiny1)-3-quinolinecarbonitrile | (M + H) | ||
162 | 4-(2,4-dichloro-5-methoxyanilino)-6- | 75-80 | 560.2 |
methoxy-7-(3-{[2-(4-morpholinyl)ethyl] | (M + H) | ||
amino}propoxy)-3-quinolinecarbonitrile | |||
163 | 7-{3-[(2-anilinoethyl)amino]propoxy}4- | 90-94 | 566.2 |
(2,4-dichloro-5-methoxyanilino)-6- | (M + H) | ||
methoxy-3-quinolinecarbonitrile | |||
164 | N-[4-(3-chloro-4-fluoroanilino)-3-cyano- | amorphous | |
7-(4-morpholinyl)-6- | |||
quinolinyl]acrylamide | |||
165 | 4-(3-chloro-4-fluoroanilino)-7-{4-[2- | 467.2 | |
(dimethylamino)ethyl]-1-piperazinyl)-6- | (M + H) | ||
nitro-3-quinolinecarbonitrile | |||
166 | 6-amino-4-(3-chloro-4-fluoroanilino)-7- | 468.2 | |
{4-[2-(dimethylamino)ethyl]-1- | (M + H), | ||
piperazinyl}-3-quinolinecarbonitrile | 234.7 | ||
(M + 2H)+2 | |||
167 | N-(4-(3-chloro-4-fluoroanilino)-3-cyano- | 522.2 | |
7-{4-[2-(dimethylamino)ethyl]-1- | (M + H) | ||
piperazinyl}-6-quinolinyl)acrylamide | 261.7 | ||
(M + 2H)+2 | |||
168 | 4-(2,4-dichloro-5-methoxyanilino)-6- | 53-55 | 559.3 |
methoxy-7-({2-[4-(2-methoxyethyl)-1- | (M + H) | ||
piperazinyl]ethyl}amino)-3- | 280.2 | ||
quinolinecarbonitrile | (M + 2H)+2 | ||
169 | 4-(2,4-dichloro-5-methoxyanilino)-6- | 190-191 | 499.4 |
methoxy-7-[3-(2H-1,2,3-triazol-2- | (M + H) | ||
yl)propoxy]-3-quinolinecarbonitrile | |||
170 | 4-(2,4-dichloro-5-methoxyanilino)-6- | 188-190 | 499.4 |
methoxy-7-[3-(1H-1,2,3-triazol-1- | (M + H) | ||
yl)propoxy]-3-quinolinecarbonitrile | |||
171 | 4-(2,4-dichloro-5-methoxyanilino)-6- | 215-218 | 456.3 |
methoxy-7-(3-thienyl)-3- | (M + H) | ||
quinolinecarbonitrile | |||
173 | 4-(2,4-dichloro-5-methoxyanilino)-6- | 210-211 | 484.1 |
methoxy-7-{[2-(2H-1,2,3-triazol-2- | (M + H) | ||
yl)ethyl]amino}-3-quinolinecarbonitrile | |||
174 | 4-(2,4-dichloro-5-methoxyanilino)-6- | 225-228 | 484.1 |
methoxy-7-{[2-(1H-1,2,3-triazol-1- | (M + H) | ||
yl)ethyl]amino}-3-quinolinecarbonitrile | |||
175 | 4-(2,4-dichloro-5-methoxyanilino)-7-(3- | 211-212 | 426.0 |
thienyl)-3-quinolinecarbonitrile | (M + H) | ||
176 | 4-(2,4-dichloro-5-methoxyanilino)-6- | 206-208 | 499.1 |
methoxy-7-[3-(1H-1,2,4-triazol-1- | (M + H) | ||
yl)propoxy]-3-quinolinecarbonitrile | |||
177 | 4-(2,4-dichloro-5-methoxyanilino)-7-[3- | 155-170 | 498.1 |
(1H-imidazol-1-yl)propoxy]-6-methoxy- | (M + H), | ||
3-quinolinecarbonitrile | 249.6 | ||
(M + 2H)+2 | |||
178 | 4-(2,4-dichloro-5-methoxyanilino)-6- | 187-188 | 498.1 |
methoxy-7-[3-(1H-pyrazol-1- | (M + H) | ||
yl)propoxy]-3-quinolinecarbonitrile | |||
179 | N-[3-cyano-4-(2,4-dichloro-5- | 57 | 599.2 |
methoxyanilino)-6-methoxy-7- | (M + H), | ||
quinolinyl]-N-[4-(4-ethyl-1- | 300.3 | ||
piperazinyl)butyl]acetamide | (M + 2H)+2 | ||
180 | N-[3-cyano-4-(2,4-dichloro-5- | 58.5-59 | 585.1 |
methoxyanilino)-6-methoxy-7- | (M + H) | ||
quinolinyl]-N-(3-(4-ethyl-1- | 293.2 | ||
piperazinyl)propyl)acetamide | (M + 2H)+2 | ||
181 | 4-(2,4-dichloro-5-methoxyanilino)-6- | 118-120 | 574.1 |
methoxy-7-{3-[4-(2-methoxyethyl)-1- | (M + H) | ||
piperazinyl]propoxy}-3- | |||
quinolinecarbonitrile | |||
182 | 4-(2,4-dichloro-5-methoxyanilino)-6- | 229-230 | 439.1 |
methoxy-7-(1H-pyrrol-1-yl)-3- | (M + H) | ||
quinolinecarbonitrile | |||
183 | 4-(4-bromo-2-fluoroanilino)-6-methoxy- | 180-182 | 483.0 |
7-[2-(1H-1,2,3-triazol-1-yl)ethoxy]-3- | (M + H) | ||
quinolinecarbonitrile | |||
184 | 4-(4-bromo-2-fluoroanilino)-6-methoxy- | 93-103 | 483.0 |
7-[2-(2H-1,2,3-triazol-2-yl)ethoxy]-3- | (M + H) | ||
quinolinecarbonitrile | |||
185 | ′4-(2,4-dichloro-5-methoxyanilino)-6- | 210-214 | 500.1 |
methoxy-7-[3-(1H-tetraazol-1- | (M + H) | ||
yl)propoxy]-3-quinolinecarbonitrile | |||
186 | 4-(2,4-dichloro-5-methoxyanilino)-6- | 228-230 | 500.0 |
methoxy-7-[3-(2H-tetraazol-2- | (M + H) | ||
yl)propoxy]-3-quinolinecarbonitrile | |||
187 | 4-(4-bromo-2-fluoroanilino)-6-methoxy- | 180-184 | 483.0 |
7-[2-(1H-1,2,3-triazol-1-yl)ethoxy]-3- | (M + H) | ||
quinolinecarbonitrile | |||
188 | 4-(4-bromo-2-fluoroanilino)-6-methoxy- | 95-103 | 483.0 |
7-[2-(2H-1,2,3-triazol-2-yl)ethoxy]-3- | (M + H) | ||
quinolinecarbonitrile | |||
189 | 4-(2,4-dichloro-5-methoxyanilino)-7{3- | 85-90 | 532.1 |
[[2-(dimethylamino)ethyl](methyl) | (M + H), | ||
amino]propoxy}-6-methoxy-3- | 266.7 | ||
quinolinecarbonitrile | (M + 2H)+2 | ||
Claims (43)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/785,269 USRE42376E1 (en) | 1998-09-29 | 2010-05-21 | Substituted 3-cyanoquinolines |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15069998P | 1998-09-29 | 1998-09-29 | |
US40586899A | 1999-09-24 | 1999-09-24 | |
US09/630,270 US6297258B1 (en) | 1998-09-29 | 2000-08-01 | Substituted 3-cyanoquinolines |
US12/785,269 USRE42376E1 (en) | 1998-09-29 | 2010-05-21 | Substituted 3-cyanoquinolines |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/630,270 Reissue US6297258B1 (en) | 1998-09-29 | 2000-08-01 | Substituted 3-cyanoquinolines |
Publications (1)
Publication Number | Publication Date |
---|---|
USRE42376E1 true USRE42376E1 (en) | 2011-05-17 |
Family
ID=26847935
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/630,270 Ceased US6297258B1 (en) | 1998-09-29 | 2000-08-01 | Substituted 3-cyanoquinolines |
US12/785,269 Active 2024-03-14 USRE42376E1 (en) | 1998-09-29 | 2010-05-21 | Substituted 3-cyanoquinolines |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/630,270 Ceased US6297258B1 (en) | 1998-09-29 | 2000-08-01 | Substituted 3-cyanoquinolines |
Country Status (1)
Country | Link |
---|---|
US (2) | US6297258B1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9421203B2 (en) | 2012-06-15 | 2016-08-23 | Institute For Cancer Research | Sensitization of cancer cells to DNA damage by inhibiting kinases essential for DNA damage checkpoint control |
US9776970B2 (en) | 2014-02-20 | 2017-10-03 | Apotex Inc. | Bosutinib forms and preparation methods thereof |
WO2020209843A1 (en) | 2019-04-09 | 2020-10-15 | Massachusetts Institute Of Technology | A micro physiological model for neuronal and muscular diseases and disorders |
Families Citing this family (93)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI1119349T1 (en) * | 1998-08-18 | 2008-12-31 | Univ California | Epidermal growth factor receptor antagonists for treating hypersecretion of mucus in the lungs |
MXPA01012899A (en) | 1999-06-21 | 2002-07-30 | Boehringer Ingelheim Pharma | Bicyclic heterocycles, medicaments containing these compounds, their use and methods for the production thereof. |
US7019012B2 (en) | 2000-12-20 | 2006-03-28 | Boehringer Ingelheim International Pharma Gmbh & Co. Kg | Quinazoline derivatives and pharmaceutical compositions containing them |
GB0126433D0 (en) * | 2001-11-03 | 2002-01-02 | Astrazeneca Ab | Compounds |
TW200813014A (en) * | 2002-03-28 | 2008-03-16 | Astrazeneca Ab | Quinazoline derivatives |
US6924285B2 (en) | 2002-03-30 | 2005-08-02 | Boehringer Ingelheim Pharma Gmbh & Co. | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them |
US20050282814A1 (en) * | 2002-10-03 | 2005-12-22 | Targegen, Inc. | Vasculostatic agents and methods of use thereof |
ES2338545T3 (en) * | 2002-12-20 | 2010-05-10 | Pfizer Products Inc. | PIRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELLULAR GROWTH. |
US7109337B2 (en) * | 2002-12-20 | 2006-09-19 | Pfizer Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
UA80767C2 (en) * | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
US20040229880A1 (en) * | 2003-02-21 | 2004-11-18 | Wyeth | 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-3-quinolinecarbonitriles for the treatment of ischemic injury |
GB0309009D0 (en) * | 2003-04-22 | 2003-05-28 | Astrazeneca Ab | Quinazoline derivatives |
GB0309850D0 (en) * | 2003-04-30 | 2003-06-04 | Astrazeneca Ab | Quinazoline derivatives |
EP1660092A2 (en) | 2003-07-03 | 2006-05-31 | Myriad Genetics, Inc. | 4-arylamino-quinazolines as activators of caspases and inducers of apoptosis |
US8309562B2 (en) * | 2003-07-03 | 2012-11-13 | Myrexis, Inc. | Compounds and therapeutical use thereof |
UA84167C2 (en) * | 2003-09-16 | 2008-09-25 | Астразенека Аб | Quinazoline derivatives as tyrosine kinase inhibitors, process for the preparation thereof (variants), pharmaceutical composition based thereon |
AU2004272345A1 (en) * | 2003-09-16 | 2005-03-24 | Astrazeneca Ab | Quinazoline derivatives |
MXPA06002963A (en) * | 2003-09-16 | 2006-06-14 | Astrazeneca Ab | Quinazoline derivatives as tyrosine kinase inhibitors. |
GB0321648D0 (en) * | 2003-09-16 | 2003-10-15 | Astrazeneca Ab | Quinazoline derivatives |
JP2007505878A (en) * | 2003-09-19 | 2007-03-15 | アストラゼネカ アクチボラグ | Quinazoline derivatives |
CA2538752C (en) * | 2003-09-19 | 2011-08-02 | Astrazeneca Ab | Quinazoline derivatives |
KR20060100388A (en) * | 2003-09-25 | 2006-09-20 | 아스트라제네카 아베 | Quinazoline derivatives |
GB0322409D0 (en) * | 2003-09-25 | 2003-10-29 | Astrazeneca Ab | Quinazoline derivatives |
DE10349113A1 (en) * | 2003-10-17 | 2005-05-12 | Boehringer Ingelheim Pharma | Process for the preparation of aminocrotonyl compounds |
GB0326459D0 (en) * | 2003-11-13 | 2003-12-17 | Astrazeneca Ab | Quinazoline derivatives |
PA8621501A1 (en) * | 2004-01-16 | 2005-08-10 | Wyeth Corp | QUINOLINE INTERMEDIARIES AS INHIBITORS OF THYROSINE KINASE RECEPTORS AND THE SYNTHESIS OF THE SAME |
ES2315834T3 (en) * | 2004-02-03 | 2009-04-01 | Astrazeneca Ab | DERIVATIVES OF QUINAZOLINA. |
TW200529846A (en) * | 2004-02-20 | 2005-09-16 | Wyeth Corp | 3-quinolinecarbonitrile protein kinase inhibitors |
EP2543376A1 (en) * | 2004-04-08 | 2013-01-09 | Targegen, Inc. | Benzotriazine inhibitors of kinases |
EP1746999B1 (en) | 2004-05-06 | 2011-11-16 | Warner-Lambert Company LLC | 4-phenylamino-quinazolin-6-yl-amides |
US20060205945A1 (en) * | 2004-05-14 | 2006-09-14 | Pfizer Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
WO2005111024A1 (en) | 2004-05-14 | 2005-11-24 | Pfizer Products Inc. | Pyrimidine derivatives for the treatment of abnormal cell growth |
CA2566332A1 (en) * | 2004-05-14 | 2005-11-24 | Pfizer Products Inc. | Pyrimidine derivatives for the treatment of abnormal cell growth |
EP1758887A1 (en) * | 2004-05-14 | 2007-03-07 | Pfizer Products Incorporated | Pyrimidine derivatives for the treatment of abnormal cell growth |
US20070299092A1 (en) * | 2004-05-20 | 2007-12-27 | Wyeth | Quinone Substituted Quinazoline and Quinoline Kinase Inhibitors |
WO2005118572A1 (en) * | 2004-06-04 | 2005-12-15 | Astrazeneca Ab | Quinazoline derivatives as erbb receptor tyrosine kinases |
JP5275628B2 (en) | 2004-08-25 | 2013-08-28 | ターゲジェン インコーポレーティッド | Heterocyclic compounds and methods of use |
TW200616612A (en) * | 2004-10-08 | 2006-06-01 | Wyeth Corp | Method for the teatment of polycystic kidney disease field of invention |
MX2007004833A (en) * | 2004-10-22 | 2007-05-16 | Wyeth Corp | 4 [(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-7-ethynyl-3- quinolinecarbonitriles for the treatment of ischemic injury. |
CN101124228B (en) | 2004-12-14 | 2011-06-15 | 阿斯利康(瑞典)有限公司 | Pyrazolopyrimidine compounds as antitumor agents |
EP1833482A4 (en) | 2005-01-03 | 2011-02-16 | Myriad Genetics Inc | Compounds and therapeutical use thereof |
US8258145B2 (en) * | 2005-01-03 | 2012-09-04 | Myrexis, Inc. | Method of treating brain cancer |
US10603314B2 (en) | 2005-02-03 | 2020-03-31 | The General Hospital Corporation | Method for treating gefitinib resistant cancer |
JP5054544B2 (en) * | 2005-02-26 | 2012-10-24 | アストラゼネカ アクチボラグ | Quinazoline derivatives as tyrosine kinase inhibitors |
GB0504474D0 (en) * | 2005-03-04 | 2005-04-13 | Astrazeneca Ab | Chemical compounds |
CN101155799A (en) * | 2005-03-16 | 2008-04-02 | 塔格根公司 | Pyrimidine inhibitors of kinases |
GB0508717D0 (en) * | 2005-04-29 | 2005-06-08 | Astrazeneca Ab | Chemical compounds |
GB0508715D0 (en) * | 2005-04-29 | 2005-06-08 | Astrazeneca Ab | Chemical compounds |
JP2008540656A (en) * | 2005-05-18 | 2008-11-20 | ワイス | 3-cyanoquinoline inhibitors of Tpl2 kinase and methods of making and using the same |
CA2608394A1 (en) * | 2005-05-25 | 2006-11-30 | Wyeth | Methods of preparing 3-cyano-quinolines and intermediates made thereby |
CN101203494A (en) * | 2005-05-25 | 2008-06-18 | 惠氏公司 | Methods of synthesizing substituted 3-cyanoquinolines and intermediates thereof |
WO2006127203A2 (en) * | 2005-05-25 | 2006-11-30 | Wyeth | Methods of synthesizing 6-alkylaminoquinoline derivatives |
CA2611720A1 (en) * | 2005-06-08 | 2006-12-14 | Targegen, Inc. | Methods and compositions for the treatment of ocular disorders |
ES2354457T3 (en) * | 2005-09-20 | 2011-03-15 | Astrazeneca Ab | COMPOUNDS OF 4- (1H-INDAZOL-5-IL-AMINO) -CHINAZOLINE AS INHIBITORS OF THE ERBB RECEIVER OF THYROSINE KINASE FOR THE TREATMENT OF CANCER. |
WO2007034143A1 (en) * | 2005-09-20 | 2007-03-29 | Astrazeneca Ab | Quinazoline derivatives as anticancer agents |
US8133900B2 (en) * | 2005-11-01 | 2012-03-13 | Targegen, Inc. | Use of bi-aryl meta-pyrimidine inhibitors of kinases |
US8604042B2 (en) * | 2005-11-01 | 2013-12-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
CN103626742B (en) * | 2005-11-01 | 2017-04-26 | 塔格根公司 | Bi-aryl meta-pyrimidine inhibitors of kinases |
US20070149508A1 (en) * | 2005-11-02 | 2007-06-28 | Targegen, Inc. | Six membered heteroaromatic inhibitors targeting resistant kinase mutations |
WO2007056118A1 (en) * | 2005-11-04 | 2007-05-18 | Wyeth | Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272 |
WO2007054550A1 (en) | 2005-11-11 | 2007-05-18 | Boehringer Ingelheim International Gmbh | Quinazoline derivatives for the treatment of cancer diseases |
JP2009517450A (en) * | 2005-12-02 | 2009-04-30 | アストラゼネカ アクチボラグ | 4-anilino-substituted quinazoline derivatives as tyrosine kinase inhibitors |
EP1960371B1 (en) * | 2005-12-02 | 2009-09-16 | AstraZeneca AB | Quinazoleine derivatives used as inhibitors of erbb tyrosine kinase |
DE102006011507A1 (en) * | 2006-03-14 | 2007-09-20 | Lts Lohmann Therapie-Systeme Ag | Active substance-loaded nanoparticles based on hydrophilic proteins |
TW200808728A (en) * | 2006-05-23 | 2008-02-16 | Wyeth Corp | Method of preparing 4-halogenated quinoline intermediates |
AU2007299080B2 (en) * | 2006-09-18 | 2013-04-18 | Boehringer Ingelheim International Gmbh | Method for treating cancer harboring EGFR mutations |
EP1921070A1 (en) * | 2006-11-10 | 2008-05-14 | Boehringer Ingelheim Pharma GmbH & Co. KG | Bicyclic heterocycles, medicaments comprising them, their use and process for their preparation |
WO2008095847A1 (en) * | 2007-02-06 | 2008-08-14 | Boehringer Ingelheim International Gmbh | Bicyclic heterocycles, drugs containing said compounds, use thereof, and method for production thereof |
CA2868899C (en) | 2007-06-01 | 2017-06-13 | Wyeth Llc | Treatment of imatinib resistant leukemia using 4-aminoquinoline-3-carbonitriles having mutation in the bcrabl gene |
US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
US8497369B2 (en) | 2008-02-07 | 2013-07-30 | Boehringer Ingelheim International Gmbh | Spirocyclic heterocycles medicaments containing said compounds, use thereof and method for their production |
ES2444128T3 (en) * | 2008-05-13 | 2014-02-24 | Astrazeneca Ab | New SAL-554 |
WO2009151910A2 (en) * | 2008-05-25 | 2009-12-17 | Wyeth | Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer |
KR101922096B1 (en) | 2008-06-17 | 2018-11-27 | 와이어쓰 엘엘씨 | Antineoplastic combinations containing hki-272 and vinorelbine |
CN113209121A (en) | 2008-08-04 | 2021-08-06 | 惠氏有限责任公司 | Antitumor combination of 4-anilino-3-cyanoquinoline and capecitabine |
US8648191B2 (en) * | 2008-08-08 | 2014-02-11 | Boehringer Ingelheim International Gmbh | Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them |
US20100069340A1 (en) * | 2008-09-11 | 2010-03-18 | Wyeth | Pharmaceutical compositions of an src kinase inhibitor and an aromatase inhibitor |
AU2010221818A1 (en) | 2009-03-11 | 2011-10-06 | Auckland Uniservices Limited | Prodrug forms of kinase inhibitors and their use in therapy |
EP2416774B1 (en) | 2009-04-06 | 2015-11-04 | Wyeth LLC | Treatment regimen utilizing neratinib for breast cancer |
MX2012000048A (en) | 2009-07-02 | 2012-01-27 | Wyeth Llc | 3-cyanoquinoline tablet formulations and uses thereof. |
US9545381B2 (en) | 2009-07-06 | 2017-01-17 | Boehringer Ingelheim International Gmbh | Process for drying of BIBW2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient |
ES2729677T3 (en) | 2009-11-09 | 2019-11-05 | Wyeth Llc | Spheroids of coated drugs and their uses to eliminate or reduce conditions, such as emesis and diarrhea |
EP3566697A1 (en) | 2009-11-09 | 2019-11-13 | Wyeth LLC | Tablet formulations of neratinib maleate |
MX2012011996A (en) | 2010-04-15 | 2013-11-27 | Chromocell Corp | Compounds, compositions, and methods for reducing or eliminating bitter taste. |
WO2012060847A1 (en) | 2010-11-07 | 2012-05-10 | Targegen, Inc. | Compositions and methods for treating myelofibrosis |
CN102731395B (en) * | 2011-04-15 | 2015-02-04 | 中国科学院上海药物研究所 | Intermediate compound of antitumor drug neratinib and its preparation method and use |
CN103304572A (en) * | 2012-03-09 | 2013-09-18 | 上海医药集团股份有限公司 | 3-cyanoquinoline compound as well as pharmaceutical composition and application thereof |
CN104140395B (en) * | 2013-05-08 | 2018-07-24 | 中国医学科学院药物研究所 | Butynamide derivative and its preparation method and pharmaceutical composition and purposes |
US9242965B2 (en) | 2013-12-31 | 2016-01-26 | Boehringer Ingelheim International Gmbh | Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors |
KR102431436B1 (en) | 2014-08-29 | 2022-08-10 | 테스 파마 에스.알.엘. | INHIBITORS OF α-AMINO-β-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE |
EP3359526A4 (en) | 2015-10-05 | 2019-04-03 | The Trustees of Columbia University in the City of New York | Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies |
CN107778229A (en) * | 2017-10-27 | 2018-03-09 | 广东莱佛士制药技术有限公司 | A kind of preparation method of the formonitrile HCN of 7 halo, 6 nitro, 1,4 EEDQ, 4 ketone 3 |
US20230357125A1 (en) * | 2022-05-06 | 2023-11-09 | AMPAC Fine Chemicals | Process for Catalytic Reduction of Nitro Compounds to Amines |
Citations (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0520722A1 (en) | 1991-06-28 | 1992-12-30 | Zeneca Limited | Therapeutic preparations containing quinazoline derivatives |
EP0566226A1 (en) | 1992-01-20 | 1993-10-20 | Zeneca Limited | Quinazoline derivatives |
EP0602851A1 (en) | 1992-12-10 | 1994-06-22 | Zeneca Limited | Quinazoline derivatives |
EP0635507A1 (en) | 1993-07-19 | 1995-01-25 | Zeneca Limited | Tricyclic derivatives and their use as anti-cancer agents |
EP0635498A1 (en) | 1993-07-19 | 1995-01-25 | Zeneca Limited | Quinazoline derivatives and their use as anti-cancer agents |
WO1995015758A1 (en) | 1993-12-10 | 1995-06-15 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit csf-1r receptor tyrosine kinase |
WO1995019774A1 (en) | 1994-01-25 | 1995-07-27 | Warner-Lambert Company | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
WO1995019970A1 (en) | 1994-01-25 | 1995-07-27 | Warner-Lambert Company | Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
WO1995021613A1 (en) | 1994-02-09 | 1995-08-17 | Sugen, Inc. | Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis |
WO1995023141A1 (en) | 1994-02-23 | 1995-08-31 | Pfizer Inc. | 4-heterocyclyl-substituted quinazoline derivatives, processes for their preparation and their use as anti-cancer agents |
WO1995024190A2 (en) | 1994-03-07 | 1995-09-14 | Sugen, Inc. | Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof |
US5480883A (en) | 1991-05-10 | 1996-01-02 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
WO1996009294A1 (en) | 1994-09-19 | 1996-03-28 | The Wellcome Foundation Limited | Substituted heteroaromatic compounds and their use in medicine |
WO1996033977A1 (en) | 1995-04-27 | 1996-10-31 | Zeneca Limited | Quinazoline derivatives |
WO1996033981A1 (en) | 1995-04-27 | 1996-10-31 | Zeneca Limited | Quinazoline derivative |
WO1996033979A1 (en) | 1995-04-27 | 1996-10-31 | Zeneca Limited | Quinazoline derivatives |
WO1996033978A1 (en) | 1995-04-27 | 1996-10-31 | Zeneca Limited | Quinazoline derivative |
WO1996033980A1 (en) | 1995-04-27 | 1996-10-31 | Zeneca Limited | Quinazoline derivatives |
US5686457A (en) | 1994-05-03 | 1997-11-11 | Novartis Corporation | Pyrrolopyrimidine derivatives having pharmacological activity |
WO1998002438A1 (en) | 1996-07-13 | 1998-01-22 | Glaxo Group Limited | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors |
WO1998002434A1 (en) | 1996-07-13 | 1998-01-22 | Glaxo Group Limited | Fused heterocyclic compounds as protein tyrosine kinase inhibitors |
WO1998013350A1 (en) | 1996-09-25 | 1998-04-02 | Zeneca Limited | Qinoline derivatives inhibiting the effect of growth factors such as vegf |
WO1998043960A1 (en) | 1997-04-03 | 1998-10-08 | American Cyanamid Company | Substituted 3-cyano quinolines |
WO1999061590A1 (en) * | 1998-05-29 | 1999-12-02 | The Scripps Research Institute | Methods and compositions useful for modulation of angiogenesis using tyrosine kinase src |
US6002008A (en) | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
US6288082B1 (en) * | 1998-09-29 | 2001-09-11 | American Cyanamid Company | Substituted 3-cyanoquinolines |
US6972288B1 (en) * | 1999-02-27 | 2005-12-06 | Boehringer Ingelheim Pharma Kg | 4-amino-quinazoline and quinoline derivatives having an inhibitory effect on signal transduction mediated by tyrosine kinases |
-
2000
- 2000-08-01 US US09/630,270 patent/US6297258B1/en not_active Ceased
-
2010
- 2010-05-21 US US12/785,269 patent/USRE42376E1/en active Active
Patent Citations (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5480883A (en) | 1991-05-10 | 1996-01-02 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
EP0520722A1 (en) | 1991-06-28 | 1992-12-30 | Zeneca Limited | Therapeutic preparations containing quinazoline derivatives |
EP0566226A1 (en) | 1992-01-20 | 1993-10-20 | Zeneca Limited | Quinazoline derivatives |
EP0602851A1 (en) | 1992-12-10 | 1994-06-22 | Zeneca Limited | Quinazoline derivatives |
EP0635507A1 (en) | 1993-07-19 | 1995-01-25 | Zeneca Limited | Tricyclic derivatives and their use as anti-cancer agents |
EP0635498A1 (en) | 1993-07-19 | 1995-01-25 | Zeneca Limited | Quinazoline derivatives and their use as anti-cancer agents |
WO1995015758A1 (en) | 1993-12-10 | 1995-06-15 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit csf-1r receptor tyrosine kinase |
WO1995019774A1 (en) | 1994-01-25 | 1995-07-27 | Warner-Lambert Company | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
WO1995019970A1 (en) | 1994-01-25 | 1995-07-27 | Warner-Lambert Company | Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
WO1995021613A1 (en) | 1994-02-09 | 1995-08-17 | Sugen, Inc. | Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis |
WO1995023141A1 (en) | 1994-02-23 | 1995-08-31 | Pfizer Inc. | 4-heterocyclyl-substituted quinazoline derivatives, processes for their preparation and their use as anti-cancer agents |
WO1995024190A2 (en) | 1994-03-07 | 1995-09-14 | Sugen, Inc. | Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof |
US5686457A (en) | 1994-05-03 | 1997-11-11 | Novartis Corporation | Pyrrolopyrimidine derivatives having pharmacological activity |
WO1996009294A1 (en) | 1994-09-19 | 1996-03-28 | The Wellcome Foundation Limited | Substituted heteroaromatic compounds and their use in medicine |
WO1996033977A1 (en) | 1995-04-27 | 1996-10-31 | Zeneca Limited | Quinazoline derivatives |
WO1996033981A1 (en) | 1995-04-27 | 1996-10-31 | Zeneca Limited | Quinazoline derivative |
WO1996033979A1 (en) | 1995-04-27 | 1996-10-31 | Zeneca Limited | Quinazoline derivatives |
WO1996033978A1 (en) | 1995-04-27 | 1996-10-31 | Zeneca Limited | Quinazoline derivative |
WO1996033980A1 (en) | 1995-04-27 | 1996-10-31 | Zeneca Limited | Quinazoline derivatives |
WO1998002438A1 (en) | 1996-07-13 | 1998-01-22 | Glaxo Group Limited | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors |
WO1998002434A1 (en) | 1996-07-13 | 1998-01-22 | Glaxo Group Limited | Fused heterocyclic compounds as protein tyrosine kinase inhibitors |
WO1998013350A1 (en) | 1996-09-25 | 1998-04-02 | Zeneca Limited | Qinoline derivatives inhibiting the effect of growth factors such as vegf |
WO1998043960A1 (en) | 1997-04-03 | 1998-10-08 | American Cyanamid Company | Substituted 3-cyano quinolines |
US6002008A (en) | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
WO1999061590A1 (en) * | 1998-05-29 | 1999-12-02 | The Scripps Research Institute | Methods and compositions useful for modulation of angiogenesis using tyrosine kinase src |
US6288082B1 (en) * | 1998-09-29 | 2001-09-11 | American Cyanamid Company | Substituted 3-cyanoquinolines |
US6972288B1 (en) * | 1999-02-27 | 2005-12-06 | Boehringer Ingelheim Pharma Kg | 4-amino-quinazoline and quinoline derivatives having an inhibitory effect on signal transduction mediated by tyrosine kinases |
Non-Patent Citations (25)
Title |
---|
Bridges et al., Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor, J. Med. Chem. 39:267-276 (1996). |
Bridges, A.J. et al., J. Med. Chem., 39, 267 (1996). |
Burke, T.R., "Protein-tyrosine kinase inhibitors," Drugs of the Future 17:119 (1992). |
Chang et al., Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents, J. Nat. Prod. 55:1529-1560 (1992). |
Chang, C.J. et al., J. Nat. Prod., 55, 1529 (1992). |
Dolle et al., 5,7-Dimethoxy-3-(4-pyridinyl)quinoline is a potent and selective inhibitor of human vascular beta-type platelet-derived growth factor receptor tyrosine kinase, J. Med. Chem. 37(17):2627-2629 (1994). |
Dolle, R.E. et al., J. Med. Chem., 372, 2627, (1994). |
Du et al., Abnormal polarization of EGF receptors and autocrine stimulation of cyst epithelial growth in human ADPKD, Am. J. Physiol. 269(2 Pt 1):487-495 (1995). |
Du J. et al., Am. J. Physiol., 269 (2 Pt 1), 487 (1995). |
Fry et al., A specific inhibitor of the epidermal growth factor receptor tyrosine kinase, Science 19:265(5175):1093-1095 (1994). |
Fry, D.W. et al., Science, 265, 1093 (1994). |
Gattone et al., Epidermal growth factor ameliorates autosomal recessive polycystic kidney disease in mice, Dev. Biol 169(2):504-510 (1995). |
Gattone, V.H. et al., Developmental Biology, 169(2), 504 (1995). |
Gazit et al., Tyrphostins. 5. Potent inhibitors of platelet-derived growth factor receptor tyrosine kinase: structure-activity relationships in quinoxalines, quinolines, and indole tyrphostins, J. Med. Chem., 39(11):2170-2177 (1996). |
Gazit, A. et al., J. Med. Chem., 35(11), 2170 (1996). |
Ife et al., Reversible inhibitors of the gastric (H+/K+)-ATPase. 3. 3-substituted-4-(phenylamino)quinolines, J. Med. Chem. 35(18):3413-3422 (1992). |
Ife, R.J. et al., J. Med. Chem., 35(18), 3413 (1992). |
Maguire et al., A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives, J. Med. Chem. 37:2129-2137 (1994). |
Maguire, M.P. et al., J. Med. Chem., 37, 2129 (1994). |
Nauta et al., Biliary epithelial cells from mice with congenital polycystic kidney disease are hyperresponsive to epidermal growth factor, Pediatr. Res. 37(6):755-763 (1995). |
Nauta J. et al., Pediatric Research, 37(6), 755 (1995). |
Rewcastle, A.J. et al., J. Med. Chem., 39, 267, (1996). |
Want, Bioorg & Med Chem Lett, vol. 10, pp. 2477-2480, 2000. * |
Wilson et al., Autocrine, endocrine and paracrine regulation of growth abnormalities in autosomal dominant polycystic kidney disease, Eur. J. Cell Biol. 61(1):131-138 (1993). |
Wilson, P.D. et al., Eur. J. Cell. Biol., 61(1), 131 (1993). |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9421203B2 (en) | 2012-06-15 | 2016-08-23 | Institute For Cancer Research | Sensitization of cancer cells to DNA damage by inhibiting kinases essential for DNA damage checkpoint control |
US9776970B2 (en) | 2014-02-20 | 2017-10-03 | Apotex Inc. | Bosutinib forms and preparation methods thereof |
WO2020209843A1 (en) | 2019-04-09 | 2020-10-15 | Massachusetts Institute Of Technology | A micro physiological model for neuronal and muscular diseases and disorders |
Also Published As
Publication number | Publication date |
---|---|
US6297258B1 (en) | 2001-10-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
USRE42376E1 (en) | Substituted 3-cyanoquinolines | |
EP2253620B1 (en) | Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors | |
US6288082B1 (en) | Substituted 3-cyanoquinolines | |
EP1117659B1 (en) | Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors | |
US6002008A (en) | Substituted 3-cyano quinolines | |
EP0973746B1 (en) | Substituted 3-cyano quinolines | |
US6548496B2 (en) | Substituted 3-cyano-[1.7], [1.5], and [1.8] naphthyridine inhibitors of tyrosine kinases | |
AU2007201934B2 (en) | Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors | |
AU2012209038B2 (en) | Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors | |
MXPA01003227A (en) | Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors | |
MXPA01003230A (en) | Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: WYETH HOLDINGS CORPORATION, NEW JERSEY Free format text: CHANGE OF NAME;ASSIGNOR:AMERICAN CYANAMID COMPANY;REEL/FRAME:024426/0347 Effective date: 20021231 Owner name: AMERICAN CYANAMID COMPANY, NEW JERSEY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:WISSNER, ALLAN;TSOU, HWEI-RU;BERGER, DAN M.;AND OTHERS;SIGNING DATES FROM 19981120 TO 19981125;REEL/FRAME:024426/0317 |
|
PTEF | Application for a patent term extension |
Free format text: PRODUCT NAME: BOSULIF (BOSUTINIB); REQUESTED FOR 1664 DAYS Filing date: 20121031 Expiry date: 20190924 |
|
FPAY | Fee payment |
Year of fee payment: 12 |
|
AS | Assignment |
Owner name: WYETH HOLDINGS LLC, NEW JERSEY Free format text: CHANGE OF NAME;ASSIGNOR:WYETH HOLDINGS CORPORATION;REEL/FRAME:031636/0645 Effective date: 20131025 |
|
AS | Assignment |
Owner name: WYETH HOLDINGS LLC, NEW YORK Free format text: ASSIGNEE ADDRESS CORRECTION;ASSIGNOR:WYETH HOLDINGS CORPORATION;REEL/FRAME:039655/0704 Effective date: 20131025 |
|
PTEG | Grant of a patent term extension |
Free format text: PRODUCT NAME: BOSULIF (BOSUTINIB) Filing date: 20121031 Expiry date: 20190924 Extension date: 20240413 |
|
CC | Certificate of correction | ||
AS | Assignment |
Owner name: WYETH HOLDINGS LLC, NEW YORK Free format text: ASSIGNEE ADDRESS CORRECTIOIN;ASSIGNOR:WYETH HOLDINGS LLC;REEL/FRAME:063165/0467 Effective date: 20230307 |